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CHAPTER ONE:
INTRODUCTION AND OUTLINE OF THIS THESIS
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INTRODUCTION
Dupuytren’s Disease is a f ibromatosis of the palmar fascias of the hand and fingers, 
which often leads to extension deficit.  Patients may develop problems using their 
hands in daily activities. The cause is not yet fully elucidated. It seems however, that 
smoking, excessive alcohol consumption, male gender, diabetes mellitus, epilepsy 
and possibly performing heavy manual labor increase the chances of getting the 
disease (Leclercq 2000, Abe 2004). Dupuytren’s Disease is most common among 
Caucasians living in or originating from North-West Europe. The prevalence in 
a country is strongly influenced by the study parameters and varies from 0.2 to 
56% (Ross 1999, Wilbrand 1999, Gudmundsson 2000, Thurston 2003, Zerajic 2004, 
Hindocha 2006, Degreef 2010). Especially men aged 50 years and over are affected 
but as age progresses, the prevalence among women increases to a 1:1 ratio in the 
ninth decade of life (Anthony 2008). There is a familial predisposition, suggesting a 
genetic origin. The complete genetic profile of Dupuytren’s Disease is not yet fully 
unraveled (Rehman et al,  2008, Hindocha et al 2006, Bayat et al,  2003), but work from 
a consortium of Dupuytren study groups from the UK, Germany and initiated and 
coordinated in Groningen, The Netherlands, has recently revealed nine susceptibility 
loci and a role for the WNT-signalling pathway in the pathogenesis of the disease 
(Dolmans et al.  2011).
DIAGNOSIS
Dupuytren’s Disease is a clinical diagnosis that can be made easily in most cases. 
However, the first manifestations of DD may cause very subtle irregularities in the 
palm, which can be confused with other diseases, even by an experienced clinician. 
When the nodules start to grow and appear in the distal palm or the base of the finger, 
it becomes easier to diagnose. In the initial phase, the nodules may be painful when 
compressed, but this sign usually disappears with time. Skin pits are the earliest 
signs of contraction of some of the affected fibers as is blanching of the skin during 
extension. Nevertheless, the differential diagnosis of Dupuytren’s Disease in this stage 
stil l  is extensive: ganglion and inclusion cysts, occupational hyperkeratosis,  
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callous formation, tenosynovitis, giant cell tumours, and epitheloid sarcoma have to be 
ruled out (Rayan 1999). Once the disease progresses, cords start to appear. By the time 
contractures emerge, the diagnosis of Dupuytren’s disease is hard to miss, although 
the differential diagnosis of dermal contracture as in burns, bowstringing following 
damage to the pulley system, f lexor tendon adhesions and intrinsic joint contractures 
should be considered. 
The area around the distal interphalangeal joint (DIP joint) is rarely affected and 
f lexion deformities there are scarce, but a Boutonniere deformity may develop. 
Dupuytren’s sequelae are usually located on the ulnar side of the hand and the fourth 
digit is mostly affected (James et al,  1952). Dupuytren’s Disease is often not only 
restricted to the fascia, but also the surrounding subcutaneous tissue and the skin can 
be involved (Meyerding et al,  1941).
Associated fibromatoses, also referred to as ectopic lesions, are Peyronie’s disease 
(fibromatosis of the tunica albuginea), which may lead to a curvature of the penis in 
erection, and Ledderhose’s Disease (plantar fibromatosis), which implies the formation 
of nodules in the plantar fascia which may cause walking problems. Besides, in 
patients with DD sometimes nodules appear on the dorsum of the PIP-joints: Garrod’s 
knuckle pads.
PROGNOSIS
The number of treatment options for Dupuytren’s Disease has increased in the last 
decades, but research into their effectiveness with high levels of evidence is limited. 
There is at present no cure for Dupuytren’s Disease, and Dupuytren’s Disease should 
be regarded as a chronic il lness. Therefore, in most cases after treatment, new 
pathological tissue is formed in the previously operated field and besides; extension 
of the disease into new locations is inevitable. Both events often lead to new 
contractures. There are risk factors that have been suggested to influence the time of 
occurrence and severity of recurrence. Hueston was the first to coin the term diathesis 
for high-risk patients (Hueston 1984).  
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The risk of recurrence is higher if the first signs of the disease occur before the age of 
40, if close relatives are affected or if ectopic lesions are present (Hindocha 2006).  
Bilateral disease, radial involvement and fifth digit involvement have been named as 
other risk factors for a more aggressive disease course (Abe et al. ,  2004). Moreover 
each treatment gives its own specific risk for recurrence. All these factors together 
determine the disease course; this should be taken into consideration when 
counselling a patient and proposing a treatment option.
TREATMENT OPTIONS
Treatment options can be divided into either surgical or non-surgical. Surgical 
procedures in their turn can be subdivided into minimally invasive and invasive 
procedures. Among the many options, which will all be described in detail in Chapter 
2, two of the most commonly performed surgical treatment modalities are limited 
fasciectomy, and percutaneous needle fasciotomy. In most countries, including the 
Netherlands, limited fasciectomy is the most frequently practiced treatment for 
Dupuytren’s Disease. Percutaneous needle fasciotomy is a less invasive technique that 
has been reinvented and has gained increasing popularity n the last decades among 
others due to its shorter recovery period.
Limited Fasciectomy
In limited fasciectomy, after elevation of the skin preferably in a plane between healthy 
skin and subcutis on one hand and the fibromatosis on the other, all macroscopically 
abnormal tissues are excised while care is taken to preserve the neurovascular bundles 
and the tendon sheet. There is global consensus that intervention is indicated for 
progressing contractures of at least 30˚ in one of the joints. The treatment should 
preferably be performed before a contracture of 60˚ has developed.  A contracture 
of > 60˚, especially in the PIP joint, is more difficult to correct, because it may be 
accompanied by shortening of the check rein and collateral ligaments, and attenuation 
of the central extensor slip, which makes durable correction very difficult (Smith 
&Breed 1994). 
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As the thickening and shortening can displace the neurovascular bundles, these could 
be damaged during the intervention. This complication is reported in 0-2% of the 
patients during the first surgical intervention and up to 10% of patients if a recurrence 
is treated (Coert et al. ,  2006). The total cumulative risk for complications is reported 
in 3.6% - 39.1% of cases, but apart from damage of the neurovascular bundle most 
other complications can be treated conservatively, an example being minor wound 
healing issues (Clibbon et al. ,  2001, McFarlane and McGrouther 1990, Denkler 2010). 
A major disadvantage of limited fasciectomy is that on average it takes 6 weeks before 
the patient has regained full use of the treated hand and some hands remain stiff after 
treatment.
Recurrence rates after fasciectomy differ enormously, from 2-73% (McFarlane 1990, 
Jurisic 2008). However, the reader of the literature on Dupuytren’s Disease should 
realise that “recurrence” is an il l-defined entity. During the course of this study we 
were once again confronted with the fact that this makes comparison between studies 
almost impossible. 
Percutaneous needle fasciotomy or aponeurotomy
At the end of the seventies of the previous century a group of French rheumatologists 
revived and refined the original method of treatment of fasciotomy suggested by 
Henry Cline of London in 1777 (Cline 1777). This was originally an open transsection 
of pathological cords. In the current practise the affected cords are weakened or cut 
percutaneously under local anesthesia with the help of an injection needle.
In experienced hands the cumulative risk for complications was found to be lower in 
needle fasciotomy than in limited fasciectomy (Badois 1993). Adverse events included 
skin breaks (20 hands, 16% of cases), digital dysesthesia due to nerve damage (3 
patients, 2% of cases), and local infection (3 patients, 2% of cases) (Badois 1993). 
Because of its minimal invasiveness, limited amount of complications and quick 
functional recovery, the intervention is seen by some as a panacea for the treatment 
of Dupuytren’s Disease and has gained great popularity among patients on different 
Internet forums (for websites, the reader is referred to References 14, 15, 16). 
Long-term follow up studies on PNF are scarce. However, from those available it can 
be concluded that a major drawback is early recurrence with a cumulative rate of 58% 
after three years in a study of Foucher and of 50% after 5 years in a study by Badois 
(Foucher 2003, Badois 1993).  
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It should be noted again that Badois used an ill-defined definition of recurrence. 
Moreover, it is currently unknown how effective PNF is as a treatment for recurrent 
disease, and there are no reports available on its long-term outcome in the treatment 
of recurrence. It is possible that PNF, although hampered by a higher recurrence rate 
than LF, can postpone a more invasive treatment, such as dermofasciectomy or limited 
fasciectomy.
Limited fasciectomy versus percutanous needle fasciotomy
The ideal treatment for Dupuytren’s disease is one, which is easy and quick to perform, 
causes little treatment burden, has little risk of complications and a fast recovery of 
function, and a long disease-free period.  Needle fasciotomy is elegant because of 
its minimally invasive character, and seems to meet many of the criteria, although 
recurrence rates seem high. Limited fasciectomy has for long served well as standard 
treatment, but the major drawback is a prolonged recovery. 
Definitions of treatment outcome and recurrence rates
To compare outcomes in treatment regimens for Dupuytren’s disease, it is essential 
that information about the success of different surgical approaches be presented in the 
same way in all studies. This also accounts for recurrence rates.
Comparison for LF and PNF on the basis of the medical literature is difficult if not 
impossible. This is f irst of all due to the fact that research on percutaneous needle 
fasciotomy is limited to date. Another problem is the fact that one of the major 
outcome parameters, “recurrence”, is used for very diverse conditions in literature. The 
most commonly used definition, “reappearance of Dupuytren’s tissue in a previously 
operated zone” (Mc Farlane & McGrouther 1990), cannot be used in percutaneous 
needle fasciotomy, since in PNF no tissue is removed.
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AIMS OF THIS THESIS
The main aim of this thesis was to study the short-term efficacy and recovery pattern, 
and complication rates, and the medium (3 yrs) and long-term (5 yrs) recurrence rates 
of percutaneous needle fasciotomy (PNF) for Dupuytren’s disease, and compare the 
treatment modality on these items to limited fasciectomy (LF) in a randomised clinical 
trial.  To this aim an extensive study protocol was designed in concordance with 
the Dutch Law for scientific research on Humans (WMO) and approved in January 
2002 (protocol number 02.0107). The trial was registered at ISRCTN, registration 
number ISRCTN 58554745. In addition, and with the aim to fil l  a knowledge gap, 
we investigated the effectiveness and outcome of PNF as a treatment modality for 
recurrent disease and its long-term outcome.
OUTLINE OF THIS THESIS
Chapter 2 gives  a full overview of all currently available treatment options for 
Dupuytren’s Disease; a review of the medical literature was performed to il lustrate all 
treatment modalities with their pro’s and con’s. 
Before embarking on the RCT, a pilot study was performed to investigate if our results 
of percutaneous needle fasciotomy were comparable to those of others who have 
reported on this technique. The results of this pilot study will be presented in  
Chapter 3 . 
Chapters 4, 5 and 6  are devoted to the randomized clinical trial that compares LF and 
PNF.
In chapter 4 ,  the patient population of the RCT will be presented together with the 
randomisation procedure, the details of the treatments employed, all pre- and post-
operative assessment tools and the immediate and 6 weeks results of our randomised 
controlled study, including the complications of limited fasciectomy and percutaneous 
needle fasciotomy. The primary outcome parameter is total passive extension deficit 
(TPED) reduction and secondary outcome parameters are complication rate, patient’s 
satisfaction and hand function recovery as investigated by DASH.
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Chapter 5 reports on the intermediate, 3-years follow-up results. This study focuses 
primarily on recurrence figures and their comparison to data available in the 
literature.
Chapter 6  encompasses the study of the 5-year postoperative results of both treatment 
modalities and compares those also to the recurrence figures from studies using 
collagenase. Besides it investigates if Dupuytren’s diathesis and other demographics 
influence the risk of recurrent disease. It also reports on satisfaction of patients and 
their preference for subsequent treatment – if desired.
Chapter 7  describes the effectiveness and long-term outcome of PNF for recurrent 
Dupuytren’s disease.
Chapter 8  describes a literature study, designed to list definitions and rates of 
contracture correction and recurrence in patients undergoing surgical treatment of 
Dupuytren’s contracture. This study was done to make future meaningful comparison 
of results achieved with different surgical interventions possible.
Chapter 9  summarizes the conclusions that can be drawn from this thesis and provides 
a general discussion of the complete work.
Chapter 10  is a Dutch translation of Chapter 9.
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CHAPTER TWO:
TREATMENT OF DUPUYTREN’S DISEASE,  
AN OVERVIEW OF OPTIONS
 
 
This chapter has in extended form been published as: 
Van Rijssen A.L., Werker P.M.N. Ned Tijdschr Geneeskd. 2009;153:A129. 
& 
Van Rijssen A.L. and Werker, P.M.N. In: Charles Eaton, M. Heinrich Seegenschmiedt, 
Ardeshir Bayat, Giulio Gabbiani, Paul Werker, Wolfgang Wach, editors. 
Dupuytren’s Disease and Related Hyperproliferative Disorders- Principles, Research, and Clinical Perspectives. 
Springer, 2012; 35-43
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ABSTRACT
In this chapter we present a systematic overview of the current treatment options for 
Dupuytren’s Disease. Few publications on the effectiveness of these treatment options 
provide greater than level 4 evidence (expert opinion). Most hand surgeons practice 
limited fasciectomy. Dermofasciectomy is used for the treatment of recurrences due to 
the reported lower risk of recurrence. Percutaneous needle fasciotomy is a minimally 
invasive technique with good results in the short term for mild contractures, but has 
a high recurrence rate. Collagenase has been introduced to the American market and 
short-term results are promising. Some, but not all,  have reported that radiotherapy 
delays disease progression if applied in early stages of the disease.
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INTRODUCTION
Dupuytren’s Disease (DD) is a f ibromatosis of the palmer fascia of the hand and fingers, 
which often leads to f lexion deformity of especially the ulnar fingers. Patients with 
digital contracture from DD may develop difficulty using their hands in daily activities 
(Figures 1 and 2). 
Figure 1: A patient with the initial 
stages of Dupuytren’s Disease.  
The fingers can stil l  be fully extended, 
but in the hand palm at the level of the 
fourth ray a nodule and skin pitting are 
visible. 
Figure 2: The hand of a patient with 
Dupuytren’s Disease. 
There is a contracture in the proximal 
interphalangeal joint of the fifth ray. The 
distal interphalangeal joint shows com-
pensatory hyperextension, a Boutonniere 
deformity.
There is no cure for Dupuytren’s Disease, neither can it be prevented. After treatment, 
the disease may recur in the previously operated field or extend to a new location. 
There are risk factors that influence the timing and severity of recurrence. The risk 
of recurrence is higher if the onset of the disease is before the age of 50, if the disease 
occurs in close relatives or if ectopic lesions are present on the dorsum of the PIP joint 
(knuckle pads, Garrod’s pads), the penis (Peyronie’s Disease) or the foot (Ledderhose 
Disease). Bilateral disease, radial involvement and small f inger involvement are other 
known risk factors (Abe et al.  2004). There are different treatment options for Dupuy-
tren’s Disease, but high-level evidence of their effectiveness is limited. 
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Each treatment has its own specific risk for recurrence. All these factors together 
determine the prognosis; this should be taken into consideration when counselling a 
patient and proposing a treatment option.
In this chapter we give an overview of the different treatment options with the best 
available evidence (level 3 or greater). 
LITERATURE ANALYSIS
We have analysed the existing literature, using Medline and the Cochrane Library 
without date limit. The search terms were “Dupuytren’s Disease”, “Morbus Dupuytren”, 
“Dupuytren”, “fasciectomy”, “fasciotomy”, “aponeurotomy”, “radiotherapy AND Dupuy-
tren”, “splinting AND Dupuytren” and “post operative hand therapy”. For subsequent 
analysis we used only the relevant articles or abstracts in English, French or German. 
The relevance of an article was determined by the title or abstract. We found one rel-
evant systematic review, nine relevant randomized clinical trials and nine case-control 
studies. Due to this limited number of studies, we also included the cohort studies that 
reported on more than 100 cases. An overview of the treatments with their advantages 
and disadvantages is summarized in Table 1. In the analysis we followed the usual clas-
sification of levels of evidence desgined by the Centre of Evidence Based Medicine: 
•	 Level 1: At least 1 systematic review or 2 randomized clinical comparative studies 
conducted independent from each other. 
•	 Level 2: At least 2 independently conducted studies (randomized clinical trials 
of moderate quality of insufficient size) or other comparative studies (non 
randomized comparative cohort study or case- control study)
•	 Level 3: At least one study of level 2 or a non comparative study
•	 Level 4: Expert opinion 
























































































































































































































































































































































































































































































































































































































































































)   




















































   
   
   
   
   
   
















































































































































































































































































































































































































































      
      
      









































































































28 Treatment for Dupuytren’s disease: An overview of options
SURGICAL TREATMENT
Limited Fasciectomy
In most countries limited fasciectomy is the most frequently practiced treatment for 
Dupuytren’s Disease. Only abnormal tissues are excised while care is taken to preserve 
unaffected fascia and neurovascular bundles (figure 3).
Figure 3: Surgical treatment of Dupuytren’s Contracture. 
The fibrotic tissue that caused the contracture has been removed via a zigzag Bruner 
incision in the finger and palm.  
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Indications:  This intervention is indicated for painful nodules that do not respond to 
conservative measures (padded gloves) or for progressing contractures of at least 30˚ 
in one of the joints. The treatment should preferably be performed before a contrac-
ture of 60˚ has developed. PIP joint contracture greater than 60˚ is more difficult to 
correct, because it may be accompanied by contracture of the checkrein and collateral 
ligaments (Misra et al.  2007) and by lengthening of the extensor mechanism (Smith 
and Breed 1994).
Disadvantages:  As the thickening and shortening can displace the neurovascular 
bundles, these could be damaged during the intervention. This complication rate is 
reported in 0-2% of the patients during the first surgical intervention and up to 10% 
of patients in recurrent cases. The total cumulative risk for complications is 19% 
whereby we note that apart from damage of the neurovascular bundle most other 
complications are minor such as wound healing issues (Clibbon et al. ,  2001, McFarlane 
and McGrouther 1990). The probability of recurrence after limited fasciectomy is 41% 
within 5 years (Foucher et al,  1992). Recurrence rates differ enormously, from 2-73% 
(McFarlane 1990, Jurisic 2008). Another disadvantage of limited fasciectomy is that on 
average it takes 6 weeks before the patient can use the treated hand again fully. 
Segmental Fasciectomy
In Belgium, Moermans popularized segmental fasciectomy. In this operation 1 cm 
segments of the diseased fascia are removed. The authors found decreased morbidity, 
quicker recovery but similar recurrence rates, when comparing their results to those 
reported in the literature (Moermans 1996). 
Radical Fasciectomy
Radical fasciectomy, popular in the 1950s and early 1960s, fell out of favour because 
of a high incidence of complications and is mentioned for historical purposes (Chick 
1991). In radical fasciectomy, the fascia is widely removed but the overlying skin is 
preserved. Incisions may vary, but the operation usually is completed by the redistri-
bution of elevated skin in such a way that most of the wound can be closed. 
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Open Palm Technique
Some advocate leaving the skin in the palm over the transverse ligament of the palmar 
aponeurosis open to allow for wound drainage (McCash, 1964). This technique has 
been found to have less complications but a slightly extended duration until complete 
wound healing.
Dermofasciectomy
Dermofasciectomy is a method where, together with the affected fascia, the over-
lying skin is excised. A skin graft is used to cover the skin defect. This method is 
indicated for patients who have either a high risk for recurrence or a recurrence with 
skin involvement. The rationale for the use of dermofasciectomy comes from a cohort 
study on 143 digits, where the skin was removed in the area between the distal palmer 
crease and the PIP joint. The risk of recurrence after this radical method was only 
8.4% after 5,8 years (Armstrong et al,  2000). Similar satisfactory results with a shorter 
follow have been presented as well (Ketchum 2011). However, in this technique the 
skin grafts were used as fire breaks placed in transverse incisions. In addition to the 
disadvantages of fasciectomy there are also the disadvantages that are associated with 
harvesting and application of a skin graft. 
Percutaneous needle fasciotomy or aponeurotomy
In the 1970s, a group of French rheumatologists revived and modified the original 
method of treatment developed by Henry Cline of London in 1777 (Cline 1777). With 
percutaneous needle fasciotomy (PNF), the affected cords are weakened or cut under 
local anesthesia with the help of an injection needle (Figure 4). 
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Figure 4a and b: The hand of a patient with Dupuytren’s Contracture before and 
after treatment with percutaneous needle fasciotomy. 
A palmar cord can be seen at the level of the fifth ray (Fig a). The contracture is main-
ly in the metacarpal phalangeal joint. The contracture was cut with a needle in several 
places (black lines in Fig .b). Following treatment, the finger is straight. (Courtesy : H. 
ter Linden).
Indications.  This technique has recently gained wide popularity. It is a minimally 
invasive intervention, with a brief recovery period. The first results of this technique 
were published in 1980 by Lermusiaux and Debeyre (1980). In the 1990s, Badois et al. 
(1993) and Foucher et al.  (2001) presented their long-term results of needle fascioto-
my, the latter only using lignocaine and needle fasciotomy, without steroid injection. 
Badois et al.  (1993) performed percutaneous needle fasciotomy on 138 patients and 
found that 81% of the treated hands had good or excellent primary results, defined 
as a Tubiana classification ≤ 1 or a residual TPED of less than 45º. In the group of 
patients with Tubiana Stage IV disease pre-operatively, 48% had good results. Foucher 
and his colleagues reported an immediate improvement of 72% in their 1998 study and 
76% in their 2001 study, which included some of the patients of the first study (Fouch-
er et al. ,  1998, 2001).
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Disadvantages.  Despite the advantages in the short term, this intervention also has 
clear disadvantages. Long term follow-up of showed that the recurrence rate after 
needle fasciotomy is much higher than after limited fasciectomy. Foucher et al.  (2001) 
reviewed 100 rays treated by percutaneous needle fasciotomy after a mean of 3.2 years. 
Fifty-eight per cent showed signs of recurrence.
For patients with likelihood for high recurrence rate this treatment seems not to be 
the best treatment option.
NON-SURGICAL TREATMENT
Injections
Many non-surgical interventions have been tried out, but so far none have replaced 
surgical treatment. 
Human enzymes 
From the beginning of the 20th century it has been tried to dissolve the thickened fas-
cia various agents including pepsin, trypsin, hyaluronidase and thiosinamin (Lange-
mak, 1907). As the effects of these agents were very brief, they were abandoned.  Only 
one study in our review has been done on enzymatic fasciotomy other than collage-
nase. This was a cohort study (evidence level 3) of only 10 treated hands in 9 patients 
injected with a mixture of lignocaine, trypsin and hyaluronidase, with a follow up of 
6.5 years. After 2 to 3 years 7 patients again had a contracture with similar severity as 
before the treatment (McCarthy 1992). 
Corticosteroids
The results of the use of local injections with corticosteroids are contradictory (Baxter 
et al.  1952, Ketchum and Donahue 2000). At best, painful nodules without contrac-
tures may become less symptomatic following local depot corticosteroid injection 
(Badalemente and Hurst 2000, Ketchum and Donahue 2000). 
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Clostridial Collagenase
In the last few years, studies have been published on the use of collagenase. (Badale-
mente and Hurst, 2007, Hurst et al.  2009).  Some of these have been conducted on the 
safety and efficacy of collagenase, including a double blind randomized trial com-
paring the drug to placebo (evidence level 2) (Hurst 2009). Another study, in which 
thirty-three patients were treated with collagenase or with a placebo also investigated 
recurrences (Hurst 2007). In 87% of the therapy group the treatment was successful 
and the contracture disappeared completely. Nineteen percent had a recurrence within 
2 years. There was no effect measured in the control group. 
As of this writing, this treatment is FDA-approved in the United States and in Europe 
the drug is being tested in selected centres in a phase 3 trial.  The treatment might be 
very risky in inexperienced hands because collagenase does not differentiate between 
normal and abnormal tissues: Clostridial collagenase acts on types 1 and 3 collagen, 
which are found not only in affected fibrotic cords but also tendons and retinacular fi-
bres. Nerves have different collagen subtypes (types 2, 16, 28) (Hart 2011) and as such 
are resistant to Clostridial collagenase. 
Radiotherapy
Indications.  The largest experience with radiotherapy for Dupuytren’s comes from 
Germany. Several studies have reported that local radiotherapy delays the develop-
ment of contractures in patients who only have nodules or an extension deficit of less 
than 10˚ (Seegenschmiedt et al.  2001, Falter et al.  2001, Betz et al. ,  2010). However, a 
retrospective cohort study reported no difference in contracture between radiated and 
non-radiated hands (Weinzierl et al.  1993). 
Disadvantages.  The disadvantages of this treatment are well known. Radiotherapy is 
potentially harmful and the side effects vary from relatively harmless erythema and 
dry skin to carcinogenic effects in the long run (Falter et al.  1991). The risk of ad-
verse effects is dose-dependent. Chronic toxicity events occurred in 16% (15/95) of 
hands treated with 30 Gy of radiation and 11% (11/103) of hands treated with 21 Gy at 
3-month follow-up (Seegenschmiedt 2001). Another study reports 31.7% minor long 
term changes due to toxicity (Betz 2010). 
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An added disadvantage is the induction of f ibrosis, which may increase risk of later 
wound healing problems. Randomized clinical trials comparing radiotherapy with con-
trols are missing and necessary to fully disclose the potential of this treatment modal-
ity, as some of the outcome following radiotherapy might be the natural progression of 
early stage disease.
SPLINTING
The benefit of preoperative use of splints to prevent contractures has proved to be of 
no use. Postoperative splinting is controversial and the rationale for this only comes 
from expert opinion, the lowest level of evidence (Rives et al.  1992, Evans et al.  2002, 
Larson and Jerosch-Hold 2008). At the moment a large randomized trial on the effects 
of post-operative splinting is under way. An outline of the results will be presented in 
a book on Dupuytren’s Disease which will be available later this year (Jerosch-Herold 
et al.  2011).
CONCLUSIONS
There is a wide range of treatment options for patients with Dupuytren’s contracture. 
These options have not been compared to each other extensively. While counselling 
patients, one should give a realistic picture of the advantages and disadvantages of the 
different treatment options. The ideal treatment is one, which is quick to perform, has 
little risk of complications; allows early recovery of function with the least possible 
co-morbidity, and the longest possible disease-free period. A specialist who has expe-
rience in different techniques is the best to advise the patient. We believe that limited 
fasciectomy stil l  is the gold-standard treatment. Needle fasciotomy is elegant because 
of the minimal invasive nature, but probably has a higher percentage of recurrence. 
Therefore needle fasciotomy is in our view not ideal for relatively young patients with 
a fast progressing Dupuytren’s Contracture, although this needs to be proved by a ran-
domized study, as not much has been published on this popular treatment.  
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For this group and for the patients with a recurrence, dermofasciectomy seems more 
appropriate, although comparative research should provide evidence for this. The role 
of radiotherapy and the injection of collagenase is not yet fully elucidated yet.
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ABSTRACT
The aim of this study was to examine our results of 74 percutaneous needle fascioto-
mies for Dupuytren’s contracture. Pre-operative and postoperative total passive exten-
sion deficit was measured. Patients were seen at the outpatient clinic after a mean of 
33 months for final follow-up. Extension deficit and sensibility were measured and 
f lexor tendon function assessed. Recurrence, defined as an increase of the passive ex-
tension deficit of 30º or more compared to the immediate postoperative measurement, 
and other complications were also noted. Immediate outcome was excellent with an 
average improvement of 77%. After 32 months, we reviewed 55 rays. Their recurrence 
rate was 65%. Two patients experienced a slightly diminished sensibility on one side 
of the finger. There were no f lexor tendon injuries. This procedure has a good short-
term effect. It may be suitable for patients who want a minimally invasive treatment 
and to whom long-term results are less important. It may also have a place in delaying 
fasciectomy. 
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INTRODUCTION
The first treatment for Dupuytren’s disease, proposed in the 18th century by Henry 
Cline (1777), consisted of sectioning the pathological Dupuytren’s cords. This treat-
ment, called fasciotomy or aponeurotomy, remained in use until the end of the 19th 
century, largely because of William Adams (1892), who used the technique routinely 
and wrote extensively about it up to the last decade of the 19th century. However, soon 
after the advent of general anaesthesia in the 1840s, Sir William Fergusson introduced 
treatment by excision of the diseased fascia (Fergusson, 1842) and this, increasingly, 
became the standard operation for this condition for the next 150 years, despite being 
hampered by high complication and recurrence rates. The latter have led to attempts 
to treat Dupuytren’s disease by less-invasive alternatives, such as injection of vitamin 
E, splinting, radiation, physical therapy and dimethylsulfphoxide. Unfortunately, these 
have either proved clinically ineffective or unsuitable for clinical use (Badois et al. , 
1993).
Baxter et al.  (1952) introduced the use of local steroid injections, but, despite initial 
optimism and success in softening some nodules, this has never achieved regression 
of actual contractures. Five years later, De Seze and Debeyre (1957) combined the 
injection of local steroids with splint therapy. Although they had excellent short- term 
results, the long-term results were not satisfactory. They then introduced the use of a 
needle, as a punch to weaken the cords, after injecting a mixture of prednisolone and 
lignocaine. Thus, the new technique of ‘‘needle fasciotomy’’ was born, although, if one 
compares the size of the bevel of a needle with the size of the blades of the bistouries 
knives used by Cline and his contemporaries, one realizes that this new technique was 
little more than a revival of Cline’s technique. Because of its shorter recovery period 
and less invasive character, needle fasciotomy quickly gained favour with patients. 
The first results of this technique were published in 1980 by Lermusiaux and Debeyre 
(1980). In the 1990s, Badois et al.  (1993) and Foucher et al.  (2001) presented their 
long-term results of needle fasciotomy, the latter only using lignocaine and needle 
fasciotomy, without steroid injection.
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In this article we present our experience since early 2001 with percutaneous needle 
fasciotomy, or PNF, following a visit in February 2001 by the senior author (PMNW) 
to the French rheumatologists, Drs. Thyssedou and Lermusiaux, in Paris.
PATIENTS AND METHODS
From April 2001, percutaneous needle fasciotomy was offered to all patients with pri-
mary Dupuytren’s disease who had a clearly defined cord and a contracture of at least 
20° at either the metacarpophalangeal (MCP) joint or at the proximal interphalangeal 
(PIP) joint. Only one patient in this study underwent percutaneous needle fasciotomy 
for contracture of the distal interphalangeal (DIP) joint. Fifty-two patients were 
included in this pilot study with disease of 56 hands, in which 74 rays were treated. 
Forty-four patients were men and 8 were women. The mean age of the patients was 65 
years (SD 10). Thirty-one left and 25 right hands, including 9 middle, 29 ring and 36 
little f inger rays underwent percutaneous needle fasciotomy. Two rays were treated at 
the same operation in 16 hands and 3 rays were treated synchronously in one hand.
On initial presentation, the f lexion contractures of the MCP, PIP and DIP joints of 
involved rays were measured. These figures were added to achieve the total passive ex-
tension deficit (TPED) of each ray and classified according to Tubiana’s staging system 
(Tubiana, 1999) (Fig 1). 
Tubiana I    = TPED of 0-45° 
Tubiana II    = TPED of 45-90° 
Tubiana III    = TPED of 90-135° 
Tubiana IV    = TPED of  ≥ 135º 
TPED      = PEDMCP + PEDPIP  + PEDDIP 
TPED     = Total Passive Extension Deficit 
PED     = Passive Extension Deficit
Fig 1: The Tubiana Classification of Dupuytren’s Contracture of the Fingers.
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OPERATIVE TECHNIQUE
Percutaneous needle fasciotomy was performed as described by Lermusiaux and De-
beyre (1980). Patients were treated in an outpatient setting under local anaesthesia 
using 1ml or less of lidocaine 1% and epinephrine 1:100,000 per treatment site. After 
disinfection and draping, the cord responsible for the f lexion contracture of the ray 
was sectioned at as many levels as possible in the palm and fingers, depending on 
the location and extent of the disease, using a 25 Gauge needle mounted on an 10ml 
syringe. In those cases where a soft tissue mass was present overlying the cord, in 
between the distal palm crease and the base of the finger, the fasciotomy in the distal 
part of the palm was performed with extra care to avoid nerve damage because a soft 
tissue mass at this site can indicate the presence of a spiral nerve (Short and Watson, 
1982; Umlas et al. ,  1994). After division of the cord, the affected finger was passively 
extended to pull the ends of the sectioned cord apart and to obtain maximal release of 
the contracture. A small dressing was applied for 24 hours. Patients were encouraged 
to start f lexing and extending their f ingers immediately after treatment and to start 
using their hands normally after 24 hours. No splint was used or physiotherapy given.
All patients were seen after 1 week and the same measurements as pre-operatively were 
taken. Special attention was paid to identify possible complications, such as rupture of 
a f lexor tendon, nerve damage or skin lacerations.
Patients were reviewed after 8 to 9 months post- operatively and finally, in June 2005, 
at a mean of 33 (SD 13) months. At this f inal review, 38 of the 52 patients were avail-
able for follow up. One patient had died, two patients did not want to participate 
further in the study, two had severe health problems and nine could not be traced. At 
8 to 9 months and at f inal review, the same measurements were taken as pre- opera-
tively. In addition, light touch sensitivity, tested by light stroking of each side of the 
fingertip, and the f lexion deficit of the finger, as indicated by the distance between 
the pulp of the finger and the distal palmar crease during maximal active f lexion, were 
measured. Light touch sensitivity was compared to this sensation on the other fingers 
of the same hand.
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TUBIANA STAGE Total Passive Extension Deficit Number        
(TPED)  (n=74)    
I 0-45° 28   
II 45-90° 31
III 90-135° 14
IV ≥ 135° 1
The diseased tissue, which is stil l  present in the palm following percutaneous needle 
fasciotomy sometimes softens after the procedure and is hardly palpable. However, 
nodules usually remain unchanged. Because of this, the usual definition of recurrence, 
viz. the appearance of a new nodule or cord, cannot be used. Therefore, a recurrence 
was defined as a TPED increase during follow-up of 30° or more compared to the im-
mediate postoperative measurements. This value was chosen because we recommend 
patients to undergo treatment in our centre when a contracture reaches 30° or more.
STATISTICS
We used the paired samples t-test for comparison of pre- operative, postoperative and 
follow-up measurements. The χ2 test was used for comparing of categorical data, such 
as recurrence rates. For comparing the recurrence rates, we included Tubiana Stage III 
and Tubiana Stage IV rays in one group, because the latter contained only one digit. 
Significance was set at P ≤ 0.05 (Table 1).
RESULTS
The mean pre-operative TPED was 62° (SD 31°).
Table 1: Preoperative assessment of the fingers by the Tubiana Classification 
 
TPED = Passive Extension Deficit MCP + Passive Extension Deficit PIP + Passive Ex-
tension Deficit DIP
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One-week review
Mean TPED immediately after surgery was 18° (SD 26°), which was a mean reduction 
of TPED of 77%. The best results were obtained at the MCP joints, at which percu-
taneous needle fasciotomy achieved a mean reduction of TPED of 88%. The mean 
reduction was only 46% at the PIP joint. At the single DIP joint released in this study, 
percutaneous needle fasciotomy achieved a reduction of TPED of 75%. In respect of 
the Tubiana stages before percutaneous needle fasciotomy, there was a trend towards 
better results with the lower stages, but there was no significant difference between 
the results for different stages (Table 2). 
Table 2: Immediate postoperative results of PNF at one week (n = 74)
Nine-month review
After 9 months, 58 rays were available for review. Of these, the mean TPED now mea-
sured 21° (SD 25°). As the mean immediate postoperative result of these 58 rays was 
19°, this deterioration was not statistically different (p = 0.349).
TUBIANA STAGE Total Passive Extension Deficit Number        
(TPED)  (n=74)    
I 0-45° 28   
II 45-90° 31
III 90-135° 14
IV ≥ 135° 1
TUBIANA STAGE PNF Improvement of TPED
% SD
Tubiana I 28 80% 29
Tubiana II 31 78% 26
Tubiana III 14 65% 27
Tubiana IV 1 75%
Mean improvement 77% 27
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TUBIANA STAGE PNF Improvement of TPED
% SD
Tubiana I 11 41% 49
Tubiana II 19 50% 39
Tubiana III 1 92%
Tubiana IV 1 14%
Mean improvement 44%
Final review
Fifty-five rays (74% of the original 74 rays) in 41 hands in 38 patients were available 
for final follow-up. Of these, 23 rays (42%) in 16 hands in 15 patients had already been 
treated for recurrence, 12 by percutaneous needle fasciotomy and four by selective 
fasciectomy after a mean of 23 (SD 14) months.
The remaining 32 treated rays in 25 hands in 23 patients were seen after a mean of 33 
(SD 13) months (Table 3). The mean TPED at follow up of these 32 rays was 26° (SD 
21°), which was a mean reduction of TPED of 44% from the TPED 1 week after sur-
gery. This was a statistically significant change (P = 0.000). 
Table 3: Postoperative result at final review at a mean of 33 months
In 13 rays in 11 hands in 10 patients, the reduction of TPED was more than 30°, which 
we defined as recurrence. Therefore, the total recurrence rate in this series at a mean 
of 33 months after PNF was 36 rays. When we compared the recurrence rates for the 
different Tubiana stages at presentation using the χ2 test, assuming a linear relation-
ship between grade and recurrence, the op value was 0.18. This indicates that there 
was no statistical difference between the groups. The recurrence rates of the different 
stages are shown in Table 4.
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Table 4: Recurrence rates 
At first follow-up, 1 week after the operation, we noticed partial loss of sensation in 
one patient. The ray in which this occurred had a Stage II Tubiana contracture. At 
the patient’s request, this f inger was not explored. At final review, two patients had a 
reduction of f lexion of 1 cm between the pulp of the treated finger and the distal pal-
mar crease, which has not recovered up to now. However, there were no signs of f lexor 
tendon injury. Two further patients were found to have slightly diminished light touch 
sensation on one side of one treated finger each at f inal follow-up. This had not been 
noted at the initial postoperative review.
DISCUSSION
Badois et al.  (1993) performed percutaneous needle fasciotomy on 138 patients and 
found that 81% of the treated hands had good or excellent primary results, defined as 
a Tubiana classification ≤ 1 or a residual TPED of less than 45º. In the group of pa-
tients with Tubiana Stage IV disease pre-operatively, 48% had good results. 
Bleton et al.  (1997) performed a prospective study of percutaneous needle fasciotomy 
on 110 digits in 59 patients. Sixty-one per cent showed good results, by which these 
authors meant an improvement of more than 50%. 
TUBIANA STAGE PNF Improvement of TPED
% SD
Tubiana I 11 41% 49
Tubiana II 19 50% 39
Tubiana III 1 92%
Tubiana IV 1 14%
Mean improvement 44%
TUBIANA STAGE Improvement of TPED PNF
% Recurrence Total rays
Tubiana I 67% 16 24
Tubiana II 45% 10 22
Tubiana III and IV 89% 8 9
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Foucher and his colleagues reported an immediate improvement of 72% in their 1998 
study and 76% in their 2001 study, which included some of the patients of the first 
study (Foucher et al. ,  1998, 2001).
Immediate outcome was also very promising in our study as we achieved a reduction 
of 77% of the contracture in a total of 74 rays treated by percutaneous needle fascioto-
my. The results were particularly good at the MCP joint, where a reduction of TPED of 
88% was achieved. Results at the PIP joint were less good, with a reduction of TPED of 
only 46%.
Badois et al.  (1993) reviewed an unknown number of rays in 123 hands, which he had 
treated by percutaneous needle fasciotomy and steroid injection after 5 years. 
Sixty-nine percent of his patients stil l  had good or excellent results after 5 years, 
defined as a Tubiana Stage I TPED, or less. Nevertheless, in his series there were 43% 
who had recurrences among those who originally had had Stage I disease before percu-
taneous needle fasciotomy and 61% who had recurrence among those who were origi-
nally in Tubiana Stage IV. The overall recurrence rate in his series was 50% although 
his definition of recurrence is not stated clearly in the article.  
Foucher et al.  (2001) reviewed 100 rays treated by percutaneous needle fasciotomy 
after a mean of 3.2 years. Fifty-eight per cent showed signs of recurrence. 
Although our immediate outcome was very promising, the extension deficit was al-
ready starting to recur after 9 months. After 33 months, 23 (42%) of the treated rays 
had already undergone a second treatment for recurrence of the Dupuytren’s disease 
while an additional 13 (23%) showed signs of recurrence. The cumulative recurrence 
rate of our study was 36 of 55 rays (65%) at 33 months. 
Other authors have described long-term results of percutaneous fasciotomy using a 
scalpel, albeit defining ‘‘recurrence’’ a little differently in each study, which makes 
direct comparisons difficult. Duthie and Chesney (1997) reviewed 82 patients with 109 
digits after 10 years. Only 28 (34%) had had no further surgery. In the remainder, the 
mean time to further surgery was 60 months.  
Bryan and Ghorbal (1988) treated 44 rays and showed similar results, with a recur-
rence rate of 45% at 5.3 years. 
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From this study, we conclude that percutaneous needle fasciotomy has excellent results 
in the short term but recurrence occurs frequently and at a relatively early stage. Re-
currence rates after other treatments of Dupuytren’s disease are lower and occur later 
than after percutaneous needle fasciotomy. After selective fasciectomy, Foucher et al. 
(1992) reported a recurrence rate of 41% at 5 years and Norotte et al.  (1988) reported 
a 71% recurrence rate at 10 years. 
This leads us to the conclusion that percutaneous needle fasciotomy is suitable only 
for patients, such as the elderly, who want simple treatment without extensive wounds 
and/or functional disturbances and to achieve a good result quickly following a mini-
mally invasive surgical insult, but for whom long-term results are less important. For 
others, this procedure may have a use in postponing selective fasciectomy.
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ABSTRACT
Purpose:  The demand for percutaneous needle fasciotomy (PNF) as treatment for 
Dupuytren’s disease is increasing because of its limited invasiveness, good outcome, 
limited number of complications, quick recovery, and overall patient satisfaction. This 
randomized controlled trial was designed to test whether these short-term expecta-
tions are sound by comparing this treatment with limited fasciectomy (LF) with regard 
to these aspects.
Methods:  We treated 166 rays: 88 by PNF and 78 by LF. Total passive extension deficit 
(TPED) improvement at 1 week and at 6 weeks were the primary outcome parameters; 
patient satisfaction, hand-function recovery, and complication rate were secondary 
outcome parameters. We used the Disabilities of the Arm, Shoulder, and Hand ques-
tionnaire to measure disabilities of the upper extremity before and after treatment and 
all adverse effects and complications were recorded.
Results:  Overall TPED improvement was best at 6 weeks. In the PNF group TPED im-
proved by 63% versus 79% in the LF group; this difference was statistically significant. 
Results at the proximal interphalangeal joint were worse than those at the metacar-
pophalangeal and distal interphalangeal joints for both the PNF and LF groups. The 
rays classified before surgery as Tubiana stages I and II showed no difference between 
these treatments, but for rays higher than stage II LF clearly was superior to PNF as a 
treatment modality. The rate of major complications in the LF group was 5% versus 0% 
in the PNF group. Patient satisfaction was almost equal but direct hand function after 
treatment was considered better in the PNF group, as was the degree of discomfort 
that patients experienced. This was underscored by the Disabilities of the Arm, Shoul-
der, and Hand scores in the PNF group, which were significantly lower than those in 
the LF group at all time points measured.
Conclusions:  In the short term and in cases with a TPED of 90° or less PNF is a good 
treatment alternative to LF for treatment of Dupuytren’s disease. 
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INTRODUCTION
In 1614, Felix Plater of Switzerland in his book “Observationum in hominis affectibus” 
was the first to describe what later became known as Dupuytren’s contracture (Elliott 
1988). The first treatment for this disease was described by Cline in 1777 and con-
sisted of division of the pathologic cords (Cline 1777). The first subcutaneous fasci-
otomy was performed by Astley Cooper, whose name this treatment bears (Cooper’s 
Fasciotomy) (Elliott 1988). In subsequent centuries surgical treatment regimens for 
Dupuytren’s disease have described a complete pendulum movement: in 1834 Goyrand 
(Goyrand 1883), helped by the emergence of anaesthesia, performed limited fasci-
ectomy. Gradually surgery became more aggressive reaching a summit in the 1950’s, 
when total palmar fasciectomy was advised by McIndoe and Beare (McIndoe 1958). 
This treatment was hampered by a very high complication rate and therefore surgeons 
returned to more selective fasciectomies or LFs. In the late 1970s a group of French 
rheumatologists reintroduced the Cooper fasciotomy and performed it using a fine 
(25-gauge) needle under local anesthesia, calling it percutaneous needle fasciotomy 
(PNF) (Lermusiaux 1982). Some hand surgeons have adopted this technique and favor-
able results have been reported (Foucher 2003).
Nevertheless the technique used most frequently by hand surgeons is LF. A drawback 
of this procedure is a cumulative complication rate of 19% (McFarlane 1990). The 
most feared complication is transection of a nerve or artery, which is reported to oc-
cur in 3% of cases. Another disadvantage is the relatively long recovery period of 21 to 
58 days (Rodrigo 1976, Tubiana 1999).
In contrast most patients treated by PNF can use their hands optimally within 1 week; 
in addition complication rates of PNF have been reported to be lower than those of LF 
and the complications re- ported have been less serious (Badois 1993, Bleton 1997). 
They consist mostly of skin tears, temporary swelling, mild hematomas, and superfi-
cial infections. A much feared major complication is the rupture of a f lexor tendon, 
which is reported in 0.05% of cases. A reported disadvantage of PNF is the high recur-
rence rate of 58% after 3 years (Foucher 2003),  whereas the recurrence rate of LF has 
been reported to be 41% after 5 years (Foucher 1992).
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This study compares the short-term outcomes of PNF and LF in a randomized con-
trolled setting. Total passive extension deficit (TPED) improvement at 1 week and 6 
weeks were the primary outcome parameters and complications, patient satisfaction, 
and hand-function recovery were the secondary outcome parameters. (The TPED is 
the sum of the passive extension deficits [PEDs] of the metacarpophalangeal [MCP], 
proximal interphalangeal [PIP], and distal interphalangeal [DIP] joints.)
MATERIALS AND METHODS
Study Design
This study was designed according to and approved by the Medisch Ethishe Toetsings 
Commissie, the Dutch Medical Ethics Committee, in January 2002. Written informed 
consent was obtained from all patients.
Between August 2002 and January 2005 all patients with Dupuytren’s disease who vis-
ited the out- patient clinics of any of the 5 plastic surgeons and 4 residents from our 
Department of Plastic, Reconstructive, and Hand Surgery were considered for inclu-
sion in this trial. 
Inclusion criteria were  
(1) a f lexion contracture of at least 30° in the MCP, PIP, or DIP joints; 
(2) a clearly defined pathologic cord in the palmar fascia; and  
(3) willingness to participate in this trial.
Excluded from the study were  
(1) patients with postsurgical recurrence or extension of the disease,  
(2) patients who were not allowed to stop taking their anticoagulants,  
(3) patients generally unfit to have surgery, and  
(4) patients who were not willing to participate in this study or had a specific treat-
ment wish.
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Study candidates were referred subsequently to 1 of the 2 surgeons from our depart-
ment who performed this study (H.T.L. or P.M.N.W.). Patients were counseled about 
our study and a complete history and physical examination of both hands was per-
formed after written informed consent had been obtained.
During the examination the amount of PED of the MCP, PIP, and DIP joints was quan-
tified in degrees and translated into TPED and into the Tubiana classification (Table 
1) (Tubiana 1999).
Table 1: The Tubiana Classification of Dupuytren’s Contracture of the Fingers
Tubiana I   = TPED of 0-45° 
Tubiana II   = TPED of 45-90° 
Tubiana III    = TPED of 90-135° 
Tubiana IV   = TPED of  ≥ 135º
TPED     = PEDMCP + PEDPIP  + PEDDIP 
TPED    = Total Passive Extension Deficit 
PED    = Passive Extension Deficit
The f lexion deficit was recorded by measuring the distance from the distal palm crease 
to the pulps of the fingers while making a fist.  Sensibility was tested using Semmes-
Weinstein monofilaments. Furthermore the presence of knuckle pads; the presence or 
absence of fatty tissue between the cord and the skin distal to the distal palmar crease, 
indicating that the digital nerve possibly was relocated by a spiral cord; and the pres-
ence or absence of plantar or penile involvement were recorded.
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Randomization
A power analysis performed beforehand based on the number of complications result-
ing from both treatments as previously reported dictated the inclusion of approximate-
ly 120 hands.
Patients were asked to pull a numbered envelope out of a box that had been prepared 
at the start of the study and that contained a note reading either “Limited Fasciec-
tomy” or “Percutaneous Needle Fasciotomy.” This determined which treatment each 
patient would receive. Patients who participated in this study were treated within 1 
month after inclusion.
Questionnaires
Patients were asked to fil l  out a questionnaire about their health status and demo-
graphics and the Dutch translation of the Disabilities of the Arm, Shoulder, and Hand 
(DASH) questionnaire (Hunsaker 2002, Veehof 2002). The DASH questionnaire is a 
validated instrument used to score disabilities of the upper extremity during daily 
activities. This questionnaire consists of 30 items that address disability and symptoms 
of the upper extremity on a scale from 0 to 5. The scores are added and transformed 
into a 100-point scale. The lower the score, the less disability is experienced. The 
scores were completed by all patients before surgery and 1, 2, 3, 4, and 5 weeks after 
treatment.
Surgical Technique
All treatments were performed by the surgeons named previously in random order 
(H.T.L. and P.M.N.W.).
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Percutaneous needle fasciotomy was performed in an outpatient treatment room in the 
same way as performed by Lermusiaux and Tyssedou, the French rheumatologists who 
were visited by the senior author (P.M.N.W.) before the commencement of the study 
(Lermusiaux 1980). PNF was performed in the same fashion as in a previously con-
ducted pilot study (Van Rijssen 2006).
Patients who were allowed to interrupt the use of anticoagulants according to the 
guidelines given by the prescriber were asked to stop this medication. We did not de-
termine the level of anticoagulation.
For anesthesia we used 1% lidocaine and 1:100,000 epinephrine. The cord responsible 
for the f lexion contracture was sectioned at as many levels as possible in the palm 
and fingers, depending on the extent and location of the disease, with a 25-gauge 
needle mounted on a syringe. If fatty tissue was present between the cord and the skin 
fasciotomy in the distal part of the palm was performed with extra care taken to avoid 
a potential spiral nerve. After division of the cord the affected finger was extended 
passively to pull the ends of the sectioned cord apart and to obtain maximal release of 
the contractures. A small dressing was applied thereafter for 24 hours. Patients were 
encouraged to start practicing f lexion and extension of the fingers immediately after 
treatment. No formal hand therapy was initiated.
Limited fasciectomy was performed in the surgical theater. Either regional anesthesia 
or general anesthesia was used according to the anesthesiologist’s and patient’s prefer-
ences. A tourniquet was used in all cases. 
In the palm a transverse incision was performed with a longitudinal proximal exten-
sion over the cords and a distal extension toward the second and fourth web spaces as 
described by Skoog (Skoog 1967). In the digits a Bruner-type incision was used. After 
mobilization of the skin f laps all pathologic cords were excised under loupe magni-
fication. In the palm the transverse palmar ligament was left intact. Care was taken 
to try to preserve all digital nerves and arteries. Adversely inflicted damage to these 
structures was repaired with standard microsurgical techniques. The skin was closed 
after transposition as necessary. In case there was a shortage of skin in the palm the 
transverse incision was left open. A light compressive bandage was applied and left in 
place for 1 week. 
62 A comparison of the direct outcomes of percutaneous needle fasciotomy and limited 
fasciectomy for Dupuytren’s disease: a 6-week follow-up study.
Patients were encouraged to start practicing f lexion and extension of the fingers im-
mediately after surgery, as soon as anesthesia had resolved. Hand therapy was not 
standard but was used only as needed. The stitches were removed after a minimum of 
10 days.
Follow-Up
Patients were seen at the outpatient clinic 1 week and 6 weeks after treatment. During 
these visits the same measurements taken before surgery were taken by the surgeon us-
ing a checklist. In addition the complications of both treatments were noted.
We defined minor and major complications. Minor complications were skin fissure 
(small tears that sometimes occur at the site of skin penetration during PNF once a 
cord has been divided and the treated digit is extended) and paresthesias (tingling 
sensations at any part of the treated digit without objective disturbance of sensation at 
the tip of the digit). Major complications included infection, skin slough, hematoma, 
transected artery, suspected digital nerve injury, re-exploration, and suspected divi-
sion of a f lexor tendon.
To compare the complication rates we used these rates of minor and major complica-
tions.
We also recorded whether full f lexion of the treated digits was possible at 6 weeks. 
Flexion was defined as reduced if a f lexion deficit of 1.5 cm from the pulps to the dis-
tal palmar crease persisted.
At 1, 2, 3, 4, and 5 weeks patients were asked to fil l  out the DASH questionnaire. After 
6 weeks patients were asked to fil l  out a questionnaire about treatment satisfaction. 
They had to give marks ranging from 0 (no/very negative) to 10 (yes/very positive). 
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Demographics
A total of 125 hands (121 patients) were included; 4 patients participated with both 
hands at separate times. From those 125 hands 2 sets of data were incomplete and 6 
patients (6 hands) withdrew from the study before treatment took place. This resulted 
in a complete data set for 113 patients (117 hands), on whom 166 rays were treated. 
Eighty-eight rays were treated by PNF; 78 rays were treated by LF. In the PNF group 83 
rays were affected at the MCP joint, 57 at the PIP joint, and 10 at the DIP joint. In the 
LF group these figures were 72, 49, and 6, respectively.
Six weeks after treatment 1 patient had died of a non–treatment-related cause and 1 
set of data was lost, so there were 111 patients (115 hands) remaining.
Eighty-three percent of the patients were men. The mean age was 63 years (range, 
35– 86 y). Most of our patients were Dutch; only 2 patients were from another country 
within northern Europe. Forty-three percent of our patients reported a positive family 
history for Dupuytren’s disease.
The average time between acquiring the disease and the first visit to our clinic varied 
from 1 year to more than 20 years (average, 7 y).
Seventy percent of patients had been manual laborers during their professional lives; 
41 of these had been working with their hands for more than 30 years. Thirty-four of 
our patients had never performed heavy labor. Fifty-nine patients stated that they used 
their hands intensively during their hobbies.
The groups were equal regarding the reported comorbidity, alcohol use, and other 
demographics (Table 2). The treated sides and rays were distributed equally over both 
groups. 
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Table 2: characteristics of patients of both the PNF Group and the LF Group 
a Two-tailed Chi square test 
b Fisher’s exact test 
c Student t-test
PNF LF
57 patients 56 patients
No. % No. % P valueb
Gender
Male 49 84.5% 45 81.8% 0.705
Female 9 15.5% 10 18.2%
Dupuytren in family 23 39.7% 26 47.3% 0.075
Knuckle pads 11 19.3% 10 17.9% 0.844
Peyronie 4 7.0% 3 5.3% 0.696b
Ledderhose 5 8.8% 7 12.5 0.520
Epilepsy 2 3.5% 2 3.6% 0.975
Diabetes 9 15.8% 4 7.1% 0.170
Use of anticoagulants
Platelet aggregation inhibitors 20 35.0% 9 16.1% 0.048
Coumarine derivatives 0 0% 2 3.6%
Mean ±SD Mean ±SD P valuec
Mean age 63.9 10.6 63.6 8.9 0.855
465A comparison of the direct outcomes of percutaneous needle fasciotomy and limited 
fasciectomy for Dupuytren’s disease: a 6-week follow-up study.
Statistical Analysis
Statistical evaluation was performed using statistical software (SPSS software; SPSS 
Inc., Chicago, IL). The characteristics of both patient groups and the characteristics of 
the hands and digits were analyzed with cross tables.
Categorical data were analyzed with the chi-square test. If cells contained a number 
less than 5 we used the Fisher exact test. The rest of the data were analyzed using the 
Student t test. Because the data from the questionnaire were too skewed to use a t test 
we used a Mann-Whitney U test for analysis.
We used a t test to analyze the DASH questionnaire results. If less then 90% of the 
questionnaire was fil led in—that is, if more than 3 of the questions were missing—by 
definition the score was invalid. Data for patients who did not fil l  out the preoperative 
form or more than 1 of the following questionnaires at 1, 2, 3, 4, or 5 weeks were not 
used in the statistical analysis.
Significance was set at a p value of less than .05.
RESULTS
Primary Outcome Parameters  
Percutaneous needle fasciotomy. 
The average TPED before treatment measured 66° per ray in the PNF group. The larg-
est contractures were found at the MCP joint: 44° on average. The contractures at the 
PIP and DIP joints were 34° and 16°, respectively.
One week after PNF the mean TPED per ray was 30°, a 58% reduction from the preop-
erative TPED. This was a statistically significant reduction of the contracture (p = 0 
.001). The results at the separate joints differed, however. The best results were found 
at the MCP joint with a 67% reduction of PED; 17° of PED remained. The reduction of 
PED at the PIP joint was 34% (24° remained) and at the DIP joint was 56% (8° re-
mained).
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Five weeks later the results were better than 1 week after treatment: the overall reduc-
tion of TPED measured 63%. The results at the MCP joint stil l  were best, with a TPED 
reduction of 75%, followed by a 61% reduction at the DIP joint and a 33% reduction at 
the PIP joint (Table 3).
Table 3: The reduction of passive extension deficit (PED) one week and six weeks 
post-treatment in percentages of the original contracture 
 
a Student t-test at six weeks
Limited fasciectomy. 
Before surgery mean TPED in the LF group was 62°, and again the largest contractures 
were found at the MCP joint (mean, 42°). The contractures at the PIP and DIP joints 
measured 34° and 28°, respectively.
After 1 week the mean TPED was 15°, a reduction of 73% (p = 0 .001). Here the largest 
reduction in TPED was found at the DIP joint: 6 joints were treated and none had any 
extension deficit left.  At the MCP joint an average reduction of 83% was obtained (a 
TPED of 9° remained) and at the PIP joint the average reduction was 53% (a TPED of 
14° remained).
Six weeks after treatment the TPED had improved further, with an average reduction 
of 79%. This was caused mainly by a further reduction of the contracture at the MCP 
joint, which averaged 5°—a TPED reduction of 87%. The results at the DIP and PIP 










MCP 67 +/- 31 83 +/- 28 75 +/- 26 87 +/- 22 0.003
PIP 34 +/- 40 53 +/- 44 33 +/- 42 49 +/- 46 0.062
DIP 55 +/- 58 100 +/- 0 61 +/- 59 83 +/- 40 0.441
TPED 58 +/- 35 73 +/- 39 62 +/- 32 79 +/- 25 0.001
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joints worsened a little: the DIP reduction measured 83% and the PIP reduction mea-
sured 49% (Table 3).
Percutaneous needle fasciotomy versus limited fasciectomy. 
The preoperative TPED of the 2 groups did not differ significantly : 66° (SD, 36°) per 
ray in the PNF group versus 62° (SD, 36°) per ray in the LF group (p = 0.549). The 
Tubiana score also was equal in the 2 groups (p = 0 .226).
Limited fasciectomy resulted in a statistically significant greater reduction of the 
f lexion contractures compared with PNF (after 1 week, p = 0.002; after 6 weeks, p = 
0.001).
The results at the MCP joint differed statistically after both 1 and 6 weeks (Table 3). 
The results at the PIP joint differed significantly after 1 week and in favor of LF but 
after 6 weeks this significance has disappeared. Results at the DIP joint did not differ 
significantly.
When we analyzed the data using the Tubiana classification it appeared that PNF and 
LF have a comparable outcome if the finger is graded as Tubiana I. The higher the 
Tubiana stage, however, the more limited the effect of PNF, especially if the finger was 
staged as Tubiana III or Tubiana IV (Tables 1 and 4).
Table 4: Reduction of TPED as percentage of preoperative value following PNF  
versus LF by Tubiana grade at six weeks 
a Student t-test










MCP 67 +/- 31 83 +/- 28 75 +/- 26 87 +/- 22 0.003
PIP 34 +/- 40 53 +/- 44 33 +/- 42 49 +/- 46 0.062
DIP 55 +/- 58 100 +/- 0 61 +/- 59 83 +/- 40 0.441
TPED 58 +/- 35 73 +/- 39 62 +/- 32 79 +/- 25 0.001
PNF LF P valuea
n= 88 rays n= 76 rays
Tubiana I (PNF=28, LF = 29) 71 +/- 45 82 +/-33 0,329
Tubiana II (PNF=38, LF =32) 67 +/- 26 78 +/- 22 0,071
Tubiana III (PNF=16, LF = 11) 46 +/- 15 75 +/- 17 0,000
Tubiana IV (PNF=6 , LF = 4) 47 +/- 8 79 +/- 27 0,004
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Secondary Outcome Parameters  
Complications.  
 
Table 5 shows the relevant complication rates of the 2 groups. In the PNF group 33 
minor complications were recorded; these consisted of 29 skin fissures and 4 cases of 
paresthesia. No major complications occurred. 
Table 5: Complications at one week 
In the LF group we noted 13 minor complications (all cases of paresthesia) and 3 
major complications: infection, hematoma, and digital nerve injury. The digital nerve 
injury was inflicted in a hand in which the transverse palmar fibers had been divided 
unintentionally. During excision of the pathologic cord the nerve was lifted out of its 
bed and this was not noted. The overall cumulative complication rate therefore was 
50% in the PNF group and 30% in the LF group. If we look at the major complications 
the cumulative complication rate in the PNF group was 0% and in the LF group it was 
5%. 
PNF LF P value a
60 hands 57 hands
Infection requiring antibiotics 0 1 0.487b
Haematoma needing treatment 0 1 0.487b
Skin slough 0 0
Skin fissure 29 n.a.
Sympathetic Dystrophy 0 0
Paresthesia 4 13 0.013
Changed Semmes-Weinstein 0 1
Digital nerve injury requiring repair 0 1 0.487b
Re-operation in operating theatre 0 0
Flexor tendon division 0 0
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Besides those complications at 1 week after treatment there were 7 patients in the 
PNF group and 45 patients in the LF group with a f lexion deficit of 0.5 cm or more. 
In none of these cases, however, was this caused by a f lexor tendon division. After 
6 weeks there were no patients in the PNF group with f lexion deficits and in the LF 
group there were 19 patients with f lexion deficits (mean, 0.6 cm). Two patients stil l 
had f lexion deficits of more than 1.5 cm. Those patients did not have f lexion deficits 
before surgery. 
If a patient’s hand function did not improve as fast as expected he/she received physio-
therapy. This was true for 6 patients in the PNF group and 8 patients in the LF group.
Patient satisfaction. 
Patients treated with PNF were more satisfied with the function of the hand at 6 weeks 
than those treated by LF (p =  0.003). Limited fasciectomy gave patients significantly 
more discomfort (p = 0.002). When asked if they would choose the same treatment 
again in the future both groups answered that they would do so.
Disabilities of the arm, shoulder, and hand questionnaire. 
A total of 114 patients f il led out DASH questionnaires; however, only 50 patients from 
the PNF group and 47 patients from the LF group fil led out the questionnaires to such 
an extent that they could be processed and analyzed statistically.
Before surgery DASH scores did not differ statistically between groups: 16 (SD, 14) in 
the PNF group and 14 (SD, 12) in the LF group (p = 0.584). One week after treatment 
the mean DASH score in the PNF group had increased to a level of 19—which was not 
significantly higher than the preoperative level—and decreased to 12 after 2 weeks. 
This reduction continued, with a mean score of 9 after 5 weeks of treatment. 
In the LF group the DASH score measured 49 after 1 week and did not return to the 
preoperative level until after 5 weeks (score, 16). 
The DASH scores of both groups differed significantly at all time points after treat-
ment, with a p value of .000 at 1,2,3, and 4 weeks and a p value of .017 at 5 weeks.
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DISCUSSION
This study is the first part of a long-term study that will follow up patients with 
Dupuytren’s disease for 5 years after treatment with either PNF or LF. This article 
addresses specifically the outcome of PNF and LF in the first 6 weeks after treatment. 
This f irst part is important because it specifically investigates the postulated ben-
efits of PNF such as minimal invasiveness, quick functional recovery, equal outcome, 
patient satisfaction, and limited number of complications in a randomized controlled 
fashion. The second part is a long-term study and will focus on recurrence rate. 
For this purpose patients were randomized into 2 groups with an equal distribution 
of Tubiana degree, TPED, and demographics by means of pulling a random envelope 
out of a box. The demographics and contractures were similar to those described in 
previous studies (Foucher 1992).  We performed LF on 57 hands and PNF on 60 hands. 
Patients were treated only once in the PNF group or the LF group. We calculated a 
cumulative complication rate as previously performed by McFarlane and McGrouther 
(McFarlane1990).
Some technical points about PNF have to be made to prevent damage to nerves. Only 
a very limited amount of local anesthesia (0.1–0.2 mL) should be administered at the 
selected puncture site. The pathologic cord itself is insensible but the nerve is not if it 
is not numbed. If the nerve is approached too closely the patient will report a strong 
electric current sensation at the tip of the treated digit. The patient should be asked to 
report this immediately and the needle should be redirected in such an instance. 
One might wonder if a spiral cord presents greater risk during treatment. This is not 
the case because the course of the displaced nerve is quite standard: it lies relatively 
superficial at the junction of the palm and the base of the finger. This location should 
be avoided during treatment. In addition, because the spiral bands course deep to the 
neurovascular bundles after leaving the central band and because the neurovascular 
bundles are embedded in subcutaneous fat at that location, the presence of fat between 
the skin and the pathologic cord near the web should raise a high level of suspicion for 
a nerve displaced by a spiral cord, and it would not be logical to perform PNF at that 
location; the cord lies relatively deep. These are the main reasons why spiral nerves are 
not damaged often if the procedure is performed correctly.
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The hands of the LF group were bandaged for 1 week whereas the hands treated by 
PNF were unwrapped after 24 hours. This may have caused some bias in the results of 
hand function after 1 week. In addition hand therapy was not standard in all cases and 
was initiated only if the return of hand function was delayed. This regimen may have 
caused a higher rate of reduced f lexion in both groups.
We used DASH questionnaires to score disabilities of the upper extremity. The Dutch 
translation of the DASH questionnaire has been proven to be a reliable and valid 
instrument for assessing upper-extremity disabilities (Veehof 2002). The preoperative 
DASH scores were equal to previously reported normative data from the United States 
(Hunsaker 2002).
The results of this study concerning short-term outcome suggest that overall LF is 
superior to PNF, especially when the Tubiana degree is III or IV. Results at the DIP 
joint were not statistically different because numbers were small (10 in the PNF group 
vs 6 in the LF group). At the PIP joint the difference between LF and PNF was almost 
statistically different. Complication rates of LF were higher than those of PNF.
Patients were satisfied equally with LF and PNF but patients treated by PNF reported a 
better direct function of the hand and less discomfort after treatment.  
This was substantiated by the DASH scores, which were significantly lower in the PNF 
group, indicating that patients were less disabled after PNF than after LF in the first 5 
weeks after treatment. This was exactly what we had expected beforehand.
Percutaneous Needle Fasciotomy
Badois et al,  the French rheumatologists who reintroduced PNF, performed PNF in 
138 patients and found that 81% had good or excellent primary results, with a Tubiana 
score of 1 or less (Badois 1993). In the group of patients with stage IV disease 48% had 
good results. Duthie and Chesney performed percutaneous fasciotomy on 82 patients 
(Duthie 1997). They reported an overall improvement rate of 69%. In 1997 Bleton et 
al   performed a prospective study on 59 patients (Bleton 1997). Sixty-one percent of 
the patients had good results, with an improvement of more than 50%. Foucher et al 
reported an immediate improvement of 72% in 1998 and 76% in 2001 (Foucher 1998, 
2003).
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Our results are not as good as those described in previous studies. With a mean im-
provement of 38° or 63%, there is a discrepancy. At first thought this might have been 
caused by our inexperience. Before we started this study, however, we performed a 
pilot study in which 51 patients with a mean contracture of 61° were treated by PNF. 
Together we treated 74 rays and the mean overall improvement was 76%. This outcome 
is comparable with the outcomes of the studies described earlier. The discrepancy sug-
gests that PNF is not suitable for just any patient, but that when selected carefully part 
of the population of patients with Dupuytren’s disease could benefit very well from 
this minimally invasive treatment.
Another reason for the disappointing results could be that Badois et al performed 
PNF at a mean of 2 to 3 sessions (Badois 1993). We performed only 1 session on each 
patient.
A third reason for the difference in outcome is probably the selection criteria; Foucher 
did not treat young patients or patients with skin involvement and used PNF at an 
earlier stage than they would have performed surgery (Foucher 2003).
The primary results of PNF in our study were quite reasonable concerning Tubiana 
stages I and II, but in stages III and IV we had improvement rates of only 46% and 
47%. The results of our hands show that PNF is not suitable for the more serious con-
tractures, as also had been concluded previously by Foucher (Foucher 2003).
Limited Fasciectomy
In the literature the results after LF vary from 53% in severe contractures (Weinzweig 
1996) to 65% (Denkler 2005) and 76% (Hoet et al  1988). In this study the mean reduc-
tion of TPED was 79%.
A comparison of our results from PNF and LF show that only in stages I and II are the 
results of these treatments equal.
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Complications
Regarding complication rates in the literature our results from PNF are comparable 
with those reported by Foucher (Foucher 2003) Badois (Badois 1993( and Bleton 
(Bleton 1997). Four patients reported paresthesia, but when we used the Semmes-
Weinstein needles the sensibility had not diminished, suggesting that this was caused 
by neuropraxia. This neuropraxia was probably the result of nerve stretching during 
the procedure.
McFarlane and McGrouther in 1990 reported a cumulative complication rate of 19% 
for LF. In our series we report a complication rate of 30%. This is caused mainly by 
a high rate of paresthesia. Of the 13 patients responsible for this rate only 1 had an 
objectively diminished sensibility using Semmes-Weinstein monofilaments. We expect 
that all other cases of paresthesia will resolve in time.
As for reduced f lexion the f lexion deficit was small:  in 17 of 19 patients the distance 
between the pulp and the distal palm crease was 1 cm or less. Many patients were not 
using the hand after 6 weeks as much as they had before surgery ; this could be attrib-
utable to stiffness and discomfort at the level of the scar. We do not expect that this 
loss of f lexion is permanent in all these patients and we will follow up the patients and 
report on this.
Patient Satisfaction and DASH Scores
Patient satisfaction in the PNF and LF groups was almost equal. Although the outcome 
of PNF is significantly worse than that of LF patients apparently appreciate the fact 
that there is an immediate improvement of hand function and that they experience 
little discomfort.
The DASH scores exemplify this remarkable difference in disability of the upper ex-
tremity. After 5 weeks the differences between LF and PNF stil l  are significant. We ex-
pect, however, that the scores in the LF group will continue to decrease over time and 
end at the same level as those of the PNF group. We will report on this in the future.
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Overall PNF is less effective than LF as a treatment for Dupuytren’s disease, especially 
in cases with moderate to severe contractures. The difference is especially true at the 
MCP level. At the PIP joint the difference is borderline significant and at the DIP 
joint no difference in short-term outcome was found. The complication rate of PNF is 
low, however, and patients do not have to be admitted to the hospital. Finally, patients 
recover more quickly from PNF than from LF. Therefore PNF is useful to treat patients 
with Tubiana grade I and II disease to whom quick recovery is important. Careful se-
lection of patients helps to get maximum results from treatment with PNF.
A long-term extension of this randomized clinical trial that will address a number of 
unanswered questions about PNF versus LF, especially regarding the chance of recur-
rence, is currently underway in our centre.
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SUMMARY
In this chapter we describe the 3-year follow-up results of our randomised controlled 
trial on percutaneous needle fasciotomy (PNF) and limited fasciectomy (LF) for Du-
puytren’s disease.
This study shows that after three years recurrence after PNF (64%) is more frequent 
than after LF (9%). We also found that younger patients get recurrent disease sooner 
after treatment for Dupuytren’s disease whichever treatment they received.
Satisfaction with the results of treatment was high in both groups, but in the LF group 
higher than in the PNF group. Nevertheless, patients who had previously undergone 
PNF were keen to have their recurrences treated by PNF again. 
PNF is an appropriate treatment for elder patients who require fast recovery of hand 
function and are willing to accept the drawback of an increased recurrence rate.  
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INTRODUCTION
Percutaneous needle fasciotomy  (PNF) is a treatment for Dupuytren’s disease that 
exists in its current form since the late 1970’s. This treatment was invented by French 
Rheumatologists, but is essentially a modification of the first treatment for Dupuy-
tren’s disease ever : aponeurotomy or fasciotomy, performed by Sir Henry Cline in 
1777, the year Baron Guillaume Dupuytren was born (Cline, 1777). Recently this 
treatment regained popularity because of the growing demand for fast recovery, low 
complication rate and minimal invasiveness (Lermusiaux and Debeyre, 1980). Dis-
advantages of this technique are its lower effectiveness for moderately severe and 
severe forms of the disease (Tubiana stages 3 and 4) and its reported high recurrence 
rate (Citron and Nunez 2005, Ullah 2009, Jurisic 2008, Foucher 2001 Van Rijssen and 
Werker 2006b).
Limited fasciectomy (LF) stil l  is the most frequently performed treatment by hand 
surgeons around the globe. It is hampered by a relatively longer recovery period and 
reasonably high complications rates, especially in recurrent cases (McFarlane and 
McGrouther 1990, Rodrigo 1976, Tubiana 1999, Coert et al 2006). In our first report of 
our on-going randomized clinical trial on the comparison of LF and PNF, we showed 
that results in the lower Tubiana stages I and II were similar, but that LF was slightly 
more effective than PNF for higher Tubiana stages in Dupuytren’s disease. Importantly, 
functional recovery following treatment was significantly faster following PNF (Van 
Rijssen et al 2006a). In a pilot study we had found that recurrence rates following PNF 
after a mean of 33 months were similar to those reported by others (Van Rijssen and 
Werker 2006b).
To this date, no long-term results of randomized trials on PNF and LF have been pub-
lished. The aim of this study was to fil l  this gap. We studied the effect on Total Passive 
Extension Deficit (TPED), patient satisfaction and recurrence rates up to 3 yrs follow-
up in two groups of patients that had been randomly assigned to both treatment arms.
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METHODS
Study design
This study was designed according to and approved by the Medisch Ethische Toetsings 
Commissie, the local Medical Ethics Committee, in January 2002. 
From August 2002 to January 2005 we considered every patient with primary Dupuy-
tren’s disease who presented at our department for this study. Written consent was 
obtained from all patients.
Inclusion criteria were a Total Passive Extension Deficit (TPED) of at least 30° in the 
MCP joint, PIP joint or DIP joint, the existence of a clearly defined cord and willing-
ness to participate in this trial.
Exlusion criteria were patients who received previous surgery for Dupuytren’s disease 
on the hand they presented with, patients who were not allowed to stop their antico-
agulants, patients generally unfit for surgery, and patients with a specific treatment 
modality wish.
Study candidates were examined by either PMNW or HTL. During examination, TPED 
of MCPJ + PIPJ + DIPJ was measured, as well as f lexion deficit using a goniometer and 
sensibility using the Semmes-Weinstein monofilaments.  Patients were asked to fil l 
out a questionnaire about their health status, functional recovery, satisfaction with the 
treatment and demographics.
Randomisation
Randomization was carried out by a secretary, by means of pulling a sealed envelop 
from a box, which contained a note, stating either PNF or LF. This determined which 
treatment the patient was to receive. For elaborate patient demographics we refer to 
our previous study (Van Rijssen et al 2006a).
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Surgical Technique
Treatment was performed by HTL or PMNW in random order. Patients were treated 
within one month after inclusion in this study. 
PNF was performed as an outpatient procedure in the same way as previously de-
scribed by Lermusiaux and Tyssedou (Lermusiaux 1980). Under local anesthesia for 
the skin only, the cords were divided using a 25-gauge needle at as many places along 
the cord as necessary to achieve maximal passive extension. A small dressing was ap-
plied for 24 hours. Patients were encouraged to start practicing the hand immediately 
after the procedure. They did not receive formal hand therapy. All hands were treated 
only once.
LF was performed under general or regional anesthesia using a palmar Skoog incision 
in combination with Bruner-type incision in the digits, which allowed skin transposi-
tion if necessary. A compressive bandage was applied which the patient was instructed 
to wear for 7 days until the first visit to the outpatient clinic. Patients were encour-
aged to practice extension and f lexion of the fingers immediately after the anesthesia 
had worn off. Hand therapy was not standard but available if indicated.
Follow-up 
Following the 6 weeks interval, patients were seen in the outpatient clinic at 6 months, 
and then yearly after treatment. During this visit we recorded the amount of passive 
extension deficit of each joint and calculated the TPED, sensibility, f lexion deficit and 
signs of recurrence or extension of the disease. Patients were asked to fil l  out a ques-
tionnaire concerning their satisfaction with the treatment. Every follow-up for this 
study was performed by one of the authors.
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Definition of recurrence
Recurrence was defined as an increase of extension deficit of at least 30 degrees 
compared to the 6 weeks values as the result of disease activity in the area previously 
treated. Extension was defined as an increase of extension deficit of at least 30 degrees 
compared to the 6 weeks values due to disease activity outside the area previously 
treated.
Statistics
Statistical analysis was performed using statistical software (SPSS software, SPSS Inc. 
Chicago, IL). We used the chi square test for categorical data. The student’s t-test was 
used for recurrence and patient satisfaction. Linear-by-linear association tests were 
used to define age versus recurrence differences. Patients were stratified into the fol-
lowing groups for this purpose: 0-35 years, 36-45, 46-55, 56-65, 66-75, >75. We used 
Kaplan-Meier curves for survival. Significance was set at a p-value of less than 0.05.
RESULTS
At six weeks post treatment 111 patients were stil l  in the study and had complete data 
sets. In these patients in total 115 hands were treated, since four patients were treated 
bilaterally. Ninety-four of these patients were men. Distribution of sexes was equal in 
both treatment arms, p = 0,529. The mean age of patients at follow up was 63 years in 
both groups, p = 0,972. Fifty-four limited fasciectomies had been performed and 61 
percutaneous needle fasciotomies.
Recurrence after LF 
Three years after surgery 8 patients with 8 treated hands were lost to follow-up due to 
severe disease or death. Forty-two hands showed no signs of recurrence (91,3%), and 4 
had recurrence (8,7%). 
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Recurrence after PNF 
In the PNF group, 5 patients with 6 treated hands were lost to follow-up, 35 hands 
showed signs of recurrence (63.6%) and 20 hands showed no signs of recurrence 
(36.4%). 
LF versus PNF 
The recurrence rate in the LF group is significantly smaller, p =0,000. 
Because we did not know if the patients that had been lost to follow-up, had recurrent 
disease or not we calculated worst-case and best-case scenarios. These are il lustrated 
in Figures 1 and 2. They show that even if all lost to follow-up patients would have 
had recurring disease, the difference between LF and PNF was stil l  striking. 
Graph 1: Worst-case scenario. Kaplan-Meier survival curves with both treatment 
modalities
 
On the x-axis time is shown in years post-treatment. On the y-axis cumulative sur-
vival is shown, in which 1,0 means 100% of patients were stil l  included in the study 
(not lost to follow-up or having recurrent disease). In this case all “lost to follow-up” 
patients were allocated as having recurrent disease. 
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Graph 2: Best-case scenario. Kaplan-Meier survival curves with both treatment 
modalities
On the x-axis time is shown in years post-treatment. On the y-axis cumulative sur-
vival is shown, in which 1,0 means 100% of patients were stil l  included in the study 
(not lost to follow-up or having recurrent disease). In this case all “lost to follow-up” 
patients were allocated as having NO recurrence.
Figure 3 il lustrates differences in recurrences and percentages of patients lost to 
follow-up.
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Figure 3: Recurrence rates in the LF group and in the PNF group at 3 years
 
 
On the x-axis the 2 different treatment modalities are shown, on the y-axis the number 
of hands treated.
Figure 4: Numbers of patients who are disease-free and have recurrent disease at 
different age groups 
On the x-axis different age-groups are shown in years at time of treatment. On the y-
axis numbers of patients are shown (LF and PNF combined).
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Treatment for recurrent disease
In the LF group, one patient chose to have his recurrence treated by PNF. Three chose 
not to be treated for their recurrence. Therefore, none of the patients in the LF group 
who had recurrent disease chose to undergo LF again.
In the PNF group, of 35 patients with recurrent disease, 21 (60%) chose to undergo a 
second PNF treatment. Six patients (17%) wanted to be treated by LF and the remain-
ing 8 (23%) chose not to undergo treatment for their recurrent disease. In these pa-
tients, the increase in extension deficit did not impair their hand function.
Sensibility recovery
During LF, one patient suffered from iatrogenic digital nerve injury. This was recog-
nized immediately and the nerve was repaired microsurgically in the same session.  
His preoperative Semmes-Weinstein test was 2.83 on the affected side of the finger. 




Patients were asked the following questions: 
Q1: Are you satisfied with the results of your treatment? (0 = not at all,  10 = excellent) 
Q2: Would you choose this treatment modality again? (0 = no, 10 = yes, definitely)
The results show that although patients are significantly less satisfied with the results 
of their treatment after PNF, they are stil l  considering undergoing the same treatment 
modality again. These figures display satisfaction either at time of recurrence (when 
the study is terminated for the specific patient), or at the time of the 3-year interval 
(at the end point taken in this study).
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Table 1: 
Recurrence versus age at time of treatment
Due to small numbers of recurrence in the LF group, we were not able to draw conclu-
sions on the age-effect on recurrence between groups. However, we were able to prove 
that the higher age at time of treatment, the lower the chance of getting recurrent 
disease for both groups together, p= 0,005.  As shown in Figures 4 and 5 all patients 
older than 56 are less likely to get recurrent disease than to remain disease-free. It also 
shows that the highest age groups have the lowest recurrence rates.
Figure 5: Recurrence rates at different age groups
On the x-axis different age-groups are shown in years at time of treatment. On the 
y-axis the percentage of these patients that had a recurrence is shown (LF and PNF 
combined).
PNF LF P value
Q 1: results 6.0 8.2 0,007
Q 2: treatment modality 7.3 8.0 0.165
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DISCUSSION
This study focuses on recurrence rates in the first three years after PNF or LF. We 
randomized our patients into two groups. Patient demographics and contractures were 
equally distributed as we have shown before and were comparable to groups in other 
studies (Van Rijssen et al.  2006a). Our direct postoperative results and results at 6 
weeks post treatment were comparable to those reported in literature.
“Recurrence” after treatment for Dupuytren’s disease however, is an il l-defined entity 
in current literature. The most commonly used definition is “reappearance of Dupuy-
tren’s tissue in a previously operated zone” (Tubiana 2000, Becker 2010).   
Reported recurrence rates differ enormously : from 0-73 % for all different techniques 
combined. Comparison is difficult because of lack of standardized definitions of re-
currence and follow-up duration.
We defined recurrence as a worsening of 30º or more compared to the postoperative 
result after 6 weeks. Our definition deviates somewhat from the definition mentioned 
above. This definition of recurrence could not be used in this study however. The rea-
son for this is that after PNF the diseased tissue is stil l  present in the palm. Nodules 
that are present before the procedure often remain unchanged or soften. The cords are 
divided but over time they seem to reconnect. 
We feel that we used a reproducible and clinically important definition of recurrence. 
Reappearance of Dupuytren’s tissue does not have to impair one’s hand function. We 
chose a worsening of 30º because this corresponds to Hueston’s tabletop test and is an 
indication for surgery in our treatment centre.
Recurrence after LF
In our study, the recurrence rate after 3 years was 9%.  
Citron and Nunez reported their results on a randomized study in which they stud-
ied the differences between longitudinal incisions closed with Z-plasty or Bruner’s 
incision closed with V-Y plasties (Citron and Nunez 2005). Only one ray was treated 
in every patient. Recurrence was defined as the reappearance of Dupuytren’s tissue 
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in previously operated field. The demographics of their patients were comparable to 
those of ours. They found 33% recurrence for the former and 18% for the latter after a 
period of 2 years.
Jurisić retrospectively studied the population of Primorsko-Goranska County, Croatia, 
and found a 73% recurrence rate after partial fasciectomy after a mean follow-up of 7 
years (Jurisić 2008). Recurrence was defined as the development of new Dupuytren’s 
disease lesions including the smallest palpable nodule irrespective if it caused a con-
tracture in the same area where fasciectomy had been performed. Thirty-four percent 
of those required further surgery.
Degreef reports in a previously unpublished study a recurrence rate of 43% after seg-
mental fasciectomy with a minimum follow-up of 2 years (Degreef, this book, Chap-
ter# Section#).
Ullah et al.  performed a prospective study on limited fasciectomy in which they 
compared direct closure with the use of a “firewall” full thickness skin graft (Ullah 
2009). They found no significant difference in recurrence, which was 13.6% average 
after a follow-up of 3 years for the group treated by fasciectomy alone. The definition 
of recurrence in this article is not clear, but the text says “progressive recurrence of 
contracture”.
At this point in our study, our recurrence rates after LF are low. When we compare 
them to other studies, it seems our recurrence rate is lower than those reported in 
literature. This can partly be explained by the variations in definitions of recurrence. 
It is anticipated that recurrence rates will increase in time.
Recurrence after PNF
Compared to studies on LF, recurrences following PNF are even more il l-defined and 
hard to balance. In our study, the recurrence rate as defined by an increase in TPED 
compared to the 6 weeks results was 63% after 3 years follow-up. This f igure is very 
similar to that of previously published series. In a pilot for this study we found 65% 
recurrence after a mean of 33 months (Van Rijssen et al 2006b). Foucher reviewed 
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100 rays after a mean of 3.2 years (Foucher 2001) and found a recurrence rate of 58%. 
These similar data indicates that we executed PNF well.  Therefore we are confident 
that the longer term results, which we expect to publish within the near future will be 
reliable too. And this is even more so, since we are the first to publish a prospective 
randomized study on the results of PNF versus LF and therefore there has not been 
selection bias. 
Age versus recurrence
As Hindocha et al pointed out that age of onset less than 50 years old will increase 
chances of recurrent disease (Hindocha 2006). To our knowledge, this is the first study 
that proves that there is an overall relationship between age at treatment and chance 
for recurrence. The higher the age of the patient at time of treatment, the lower the 
chances of getting recurrent disease.
Treatment of recurring disease
Recurrence does not necessarily mean that there is a need for reoperation. Twenty-
eight percent of the patients who had a recurrence according to our definition chose 
not to undergo further treatment at that moment. This is probably because the exten-
sion deficit was less severe than the preoperative disease and did not impair hand 
function as it initially did.
Satisfaction
Satisfaction was high for both PNF and LF. Patients receiving LF were at 3 years sig-
nificantly more satisfied with the results of their treatment than those who underwent 
PNF. However, many patients who suffered recurrent disease chose to undergo PNF 
again. This indicates that many patients prefer a minor procedure with fast recovery at 
the expense of the increased chance of an early recurrence.
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CONCLUSIONS
* Recurrences after PNF are far more frequent and occur sooner than after LF
* Recurrence after PNF at three years is 63% and after LF 9%.
* Satisfaction is high for both treatment modalities, but patients treated by LF are 
significantly more satisfied with their results than those patients treated by PNF
* Many patients choose to undergo PNF as their secondary treatment in spite of the 
disadvantages named above
* No matter which treatment modality, recurrences occur more frequently in the 
younger patients than in the older patients.
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ABSTRACT 
 
Background:  The increasing armamentarium to treat Dupuytren’s disease indicates 
a need for comparative studies. Here the 5-year follow-up results of a randomized 
controlled study that compared percutaneous needle fasciotomy (PNF) and limited 
fasciectomy (LF) is presented. 
Methods:  111 patients with 115 affected hands with a minimal passive extension defi-
cit of 30° were randomly assigned to the treatment arms. Follow up was at one and six 
weeks, six months, 1,2,3,4, and 5 years after the operation. Outcome parameters were 
Total Passive Extension Deficit (TPED), patient satisfaction, f inger f lexion and sen-
sibility. Furthermore, disease extension during follow-up was recorded. The primary 
end point was recurrence in any treated ray, defined as an increase of TPED of >30o. 
Ninety-three patients reached the primary endpoint.
Results:  Recurrence rate after 5 years in the PNF group (84.9%) was significantly 
higher than in the LF group (20.9%), p < 0.001, and occurred significantly sooner in 
the PNF group (p = 0.001). Higher age at time of treatment decreased the recurrence 
rate, p=0.005. No indications were found that other diathesis characteristics influ-
enced recurrence. Patient satisfaction was high in both groups, but in the LF group 
significantly higher than in the PNF group. Despite this, many patients (53%) pre-
ferred PNF treatment in case of disease recurrence.
Conclusions:  PNF is the preferred treatment for elderly patients with Dupuytren’s 
disease and for those willing to accept the drawback of a possible early recurrence in 
the context of the advantages of PNF, such as fast recovery, low complication rate and 
minimal invasiveness.  
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INTRODUCTION 
 
Percutaneous needle fasciotomy (PNF) is a treatment for Dupuytren’s disease that was 
reinvented by French rheumatologists in the late 1970s, and is essentially a modifica-
tion of the treatment that was first suggested by Sir Henry Cline in 1777: aponeurot-
omy or fasciotomy (Lermusiaux 1980, Cline 1777). PNF is gaining popularity because 
of the growing demand for fast recovery, low complication rate, and minimal inva-
siveness (Lermusiaux 1980). In a previous report on our randomized clinical trial we 
have shown that functional recovery during the first six weeks was significantly faster 
following PNF than after limited fascietomy (LF) (Van Rijssen 2006a). We also found 
that PNF is not as effective for moderately severe and severe forms of the disease 
(Tubiana stages 3 and 4) as LF (Van Rijssen 2006). As major drawback, the reported 
recurrence rates after PNF have been relatively high (Foucher 2001, Van Rijssen 2006b, 
2011). Worldwide, hand surgeons most frequently use LF, despite its relatively longer 
recovery period and reasonably high complication rates, especially in recurrent cases 
(Citron 2005, McFarlane 1990, Rodrigo 1976, Tubiana 1999, Coert 2006, Ullah 2009, 
Jurisić 2008)
To date, a randomized controlled trial comparing the two treatments with long term 
follow up had not been performed. The purpose of the present study is to fil l  this gap 
and to report on our five years recurrence rates. This study also allowed us to analyze 
whether pre-operative disease factors predispose for recurrence. Our primary outcome 
measure was Total Passive Extension Deficit (TPED) of each treated ray. Patient satis-




This study was designed according to and approved by the local Medical Ethics Com-
mittee in January 2002. From August 2002 to January 2005 every patient with  
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Dupuytren’s disease who presented at our Department was assessed for enrolment in 
the study. Inclusion criteria were total passive extension deficit of at least 30° in any 
ray, excluding the thumb, the existence of a clearly defined palmar cord and willing-
ness to participate in the trial.  Written consent was obtained from all patients at study 
entry. Excluded were patients with postsurgical recurrence or extension of the disease 
after earlier treatment, patients who were not allowed to stop their anticoagulants, 
patients generally unfit for surgery, and patients with a specific treatment preference. 
Patients were asked to fil l  out a questionnaire about their health status and demo-
graphic characteristics and these data have been published before (Van Rijssen 2006). 
The Abe diathesis scoring system was applied at the end of the study  to evaluate its 
inf luence on recurrence and extension in our study (Abe 2004). 
The diathesis score (D) is calculated as: D = a + b + c + d + e + f,  in which “a” is bi-
lateral hand involvement (with = 1, without = 0), “b” is little f inger surgery (with = 1, 
without = 0), “c” is early onset of disease (with = 1,without = 0), “d” is plantar fibrosis 
(with = 2, without = 0), “e” is presence of knuckle pads (with = 2, without = 0), and “f ” 
is radial side involvement (with = 2, without = 0).
Randomization  (3). 
Randomization was done through the pulling of sealed envelopes by a secretary. 
Surgical technique
PNF was performed as outpatient procedure using local anaesthesia for the skin only 
(Van Rijssen 2006). Cords were divided using a 25-gauge needle at as many places as 
necessary to achieve maximal passive extension. A small dressing was applied for 24 
hours. Patients were encouraged to start practicing the hand immediately after the 
procedure. All hands were treated only once.
LF was performed under regional or general anaesthesia using a palmar Skoog inci-
sion in combination with Bruner-type incision in the digits. All diseased fascias were 
removed and the skin was closed following f lap transposition as indicated. A light 
compressive bandage was applied which the patient was instructed to wear for 7 days 
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until the first visit to the outpatient clinic. Patients were encouraged to practice exten-
sion and f lexion of the fingers immediately after the anaesthesia had worn off. 
Follow-up
Following the six weeks interval (Van Rijssen 2006), patients were seen at 6 months, 
and at 1,2,3,4 and 5 years after treatment. Follow-up investigation consisted of goni-
ometry to assess extension deficit,  assessment of sensibility and satisfaction. For the 
latter, the following two questions were asked:
Q1: How satisfied are you with the results of your treatment? (1 = not at all,  10 = ex-
cellent) 
Q2: How likely is it that you would choose this treatment modality again? (1 = no, 10 
= yes, definitely)
At the start of the study, recurrence was defined as an increase of TPED of at least 30° 
compared to the 6 weeks follow-up values in the ray previously treated. Extension was 
defined as disease activity outside the area previously treated. Recently a number of 
studies have been published using a definition of recurrence by joint (Badalamente 
2000, 2002, 2007, Hurst 2009). To enable comparison of our data with these studies, 
their definition, i.e.,  “a return of contracture (20°) in successfully treated joints”, in 
which successfully treated joints had reached a TPED of 0-5º, was also applied. 
STATISTICS
Statistical analysis was performed using statistical software version 15.0 (SPSS soft-
ware, SPSS Inc. Chicago, IL). The chi square test was used for categorical data. The 
Student’s t-test was used for recurrence and patient satisfaction. Linear regression 
analyses were performed to study age versus recurrence differences. Correlation re-
gression analyses were applied to calculate the influence of demographics on recur-
rence rate. Significance was set at a p-value of less than 0.05.
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RESULTS
In total 93 patients (84%) reached the primary end point or could be followed for 5 
years. Their demographical details are summarized in Table 1. In these 93, 125 joints 
were treated with LF and 167 joints with PNF. There were no statistical differences in 
various characteristics between the PNF and LF groups. The mean PED’s of the study 
population at the start of the study and the outcome figures at six weeks are summa-
rized in Table 2.
Table 1: Demographics and patient characteristicsrole 
LF (n = 41) PNF (n = 52) P value
Gender Male 32 44 0.42
Female 9 8
Knucklepads 6 9 0.77
Ledderhosen 7 3 0.07
Dupuytren’s in family 20 18 0.15
Epilepsy 0 2 0.21
Diabetes 4 7 0.61
Early-onset disease before 50 14 19 0.88
Abe-score > 4 5 6 0.97
Mean age (years) 63.1 62.8 0.86
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Table 2: Mean PED’s by joint, of that part of the study population that reached the 
primary end point, or completed the 5 years follow up, at the start of the study and 






















MCPJ 43o 9o 55% 41o 1o 94%
PIPJ 35o 21o 26% 32o 9o 47%
* reduction to 0-5o PED
Recurrence after LF and PNF
During five years follow-up 33 hands in 31 patients treated with LF did not develop 
recurrence (76.8%), while 9 hands did (20.9%). One hand showed extension (2.3%). 
After 5 years, only eight hands treated with PNF showed no signs of recurrence 
(15.1%). The other 45 hands (84.9%) had reached the primary end point of the study. 
The recurrence rate in the LF group was significantly smaller, p < 0.001 (95% confi-
dence interval 1,597-2,628), and recurrence occurred significantly later after LF than 
after PNF (p = 0.001). Figure 1 shows the Kaplan-Meier survival estimates of the study 
groups. For both procedures, the distribution of recurrences appeared to be normally 
distributed. For LF there were 2 recurrences at two years, 2 at three years, 3 at four 
years and 3 at 5 years. For PNF: 6 recurrences at 6 months, 10 at 1 yr, 13 at two years, 
7 at three years, 8 at four years and 1 at 5 years.
104 5-year results of a randomized clinical trial on treatment in Dupuytren’s 
disease: Percutaneous needle fasciotomy versus limited fasciectomy
Figure 1: Kaplan-Meier survival estimates for both treatment modalities
Decrease of rate of patients in the study (y-axis) with time (x-axis, in years of follow 
up) as the result of reaching the primary end point of the study (increase of TPED of 
>30o). 
Pictures 1 and 2 show a clinical example of a 61-year-old male who was treated by LF 
on the 4th digit of his left hand. After 5 years, there was no recurrence in this f inger, 
but extension of the 5th digit was noted. Pictures 3 and 4 show preoperative and post-
operative and results after one year of a 63 year old male patient who was treated by 
PNF. He later suffered from recurrent disease.
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Figure 2: Recurrence rates in different age groups
On the x-axis different age groups are shown in years at time of treatment. On the y-
axis the percentage of these patients that developed recurrence is shown (LF, PNF, and 
combined).
Although not statistically significant in the LF group, due to the small number of 
recurrences, a higher age at the time of treatment seemed to predict a delay of recur-
rence (p=0.07). In the PNF group the age-recurrence correlation was statistically 
significant at p = 0.04. When the LF and PNF groups were taken together, the older 
age group showed less recurrent disease than the younger patients, p = 0.005 (Figure 
2). No factors correlating with recurrent disease were found other than age at the time 
of treatment (Table 3). 
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Picture 1: AP view of male patient who was treated on the 4th digit of the left hand 
Age and recurrence
Picture 2: After 5 years he suffered from extension in the 5th digit
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Picture 3: Preoperative view of a 63-
year old patient before PNF on his left 
5th digit
Picture 4: The same patient as in pic-
ture 3, postoperatively after PNF of 
the 5th digit on the left hand.






Fifth digit involvement 0.06 3.10
Radial side involvement 0.39 1.29
Early onset disease 0.06 2.41
Family members with Dupuytren’s disease 0.58 1.27
Table 3: the influence of risk factors on recurrence
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Abe’s scoring system for predicting recurrence and extension
Abe’s scores for both treatment groups were calculated. Four out of 10 patients with 
recurrence or extension in the LF group had an Abe’s score higher than 4; in the PNF 
group 9 out of 45 had an Abe’s score higher than 4. These scores did not influence the 
chances of recurrence; p=0.23 in the LF group and p=0.19 in the PNF group. There-
fore, our study does not support Abe’s hypothesis; a higher score did not correlate with 
recurrence in our study. 
Choice of treatment for recurrent disease
In the LF group, four of nine patients chose to have their recurrences treated with 
PNF. Six patients (five with recurrences and one with extension) chose not to be 
treated. None of the patients in the LF group who presented with recurrent disease 
chose LF again.
Twenty-six patients out of 45 with recurrent disease in the PNF group, chose to un-
dergo a second treatment with PNF. Seven patients preferred LF. The remaining 12 
patients did not opt for treatment for recurrent disease.
Satisfaction
The average patient satisfaction score was significantly higher in the LF group (8.3), 
as compared to the PNF group (6.2, p < 0.001). The score for choosing the same 
procedure as preferred future treatment was 8.7 in the LF group, which was signifi-
cantly higher than the score of 7.0 in the PNF group (p = 0.008). The scores for both 
questions were strongly correlated to recurrent disease. In patients with recurrence, 
satisfaction with treatment results was significantly less (p < 0.001) as compared to 
the patients without recurrence (Odd’s ratio 0.61). These patients also expressed less 
preference for the same treatment (p =0.02, Odd’s ratio 0.83). 
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DISCUSSION
This study focused on Dupuytren’s disease recurrence rates that occurred during a 5 
years follow up period after treatment by percutaneous needle fasciotomy (PNF) or 
limited fasciectomy (LF). A number of definitions can be found in the literature for 
“recurrence” after treatment for Dupuytren’s disease. For example, McFarlane used 
the definition “recurrent joint contracture sufficient to require further operation” 
(McFarlane 1990). Hueston used “appearance of new Dupuytren’s tissue within the 
area cleared at operation” and this definition is the most widely used one (20). Some 
authors, such as Makela et al.  and Badois did not define “recurrence” (McFarlane 1990, 
Mäkelä 1991, Badois 1993). 
Hueston’s definition of recurrence could not be used, since in PNF no tissue is re-
moved (Hueston 1984). Therefore, recurrence was defined indirectly, i.e.,  “an increase 
of the Total Passive Extension Deficit of 30º or more in a ray compared to the result 
at 6 weeks post treatment”. This measure is reproducible and clinically more relevant 
than the other definitions. A worsening of digital extension of 30º was chosen because 
it corresponds to Hueston’s tabletop test and is considered the minimal contracture to 
qualify for surgery at our centre.
Recurrence after LF
In a previous study on the 3-year results of the same cohort of patients we found a 
recurrence rate of 9% (Van Rijssen 2011). At 5 years, the recurrence rate has increased 
to 20.9%. This f igure compares favourable to other studies, although comparison is 
hampered due to varying definitions, and a lack of 5-year follow up data from other 
studies. We found only two studies with long-term data that we consider to some 
extent relevant for comparison. Jurisić et al.  retrospectively studied the population of 
Primorsko-Goranska County in Croatia and found a 73% recurrence rate after limited 
fasciectomy and a mean follow-up of 7 years (Jurisić 2008). However, they had defined 
recurrence as the development of new Dupuytren’s disease lesions in the area where 
fasciectomy had been performed, including the smallest palpable nodule irrespective 
of a presenting contracture. Thirty-four percent of these recurrences required further 
surgery.  
110 Introduction and outline of this thesis
Foucher described his results on the open palm technique in 54 patients in 1992 with a 
5.6-year follow-up period. Recurrence was not clearly defined. The recurrence rate in 
his study was 41%.
Recurrence after PNF
In our study, 85% of the patients developed recurrence during 5 years follow-up. This 
recurrence rate is the highest ever published for PNF. Nevertheless, we believe that 
the results of others would have been similar if they had followed their cohorts for 5 
years and had used a comparable definition. In our analysis at 3 years, the recurrence 
rate was 63%. This figure is very similar to that of previously published series with 
the same follow up period. In our pilot we found 65% recurrence after a mean of 33 
months (Van Rijssen 2006b), while Foucher reviewed 100 rays after a mean of 3.2 years 
and found a recurrence rate of 58% (Foucher 2001). The only study that reported 5 
year results was from the group of Badois et al (Badois 1992). They reported a recur-
rence rate of only 50%, but their definition of recurrence is unclear. 
Recurrence after LF and PNF compared to those after treatment with collagenase
In the last decade the results of various studies on the application of collagenase for 
Dupuytren’s disease have been published (Badalamente 2000, 2002, 2007, Hurst 2009, 
Watt 2010). The results of these studies have been presented in a different man-
ner than ours. All collagenase studies looked at the effect of treatment at each joint 
individually. The treatment is defined “clinically successful” when correction of the 
deformity decreases to within 0-5˚ of full extension. 
If we reanalyze our data accordingly, 94% of the treated MP-joints in the LF group, 
and 55% in the PNF group reached this endpoint. In the PIP joint the corresponding 
figures are 47% following LF and 26% following PNF. Our results were achieved with 
only one treatment, whereas patients treated with collagenase often needed multiple 
treatment sessions. In the study by Hurst et al,  76% of MCP joints reached the primary 
endpoints and 40% of PIP joints (Hurst 2009). A comparison with our data shows that 
we achieved better results with LF than Hurst et al obtained with collagenase. A single 
treatment with PNF, however, seems to be somewhat inferior to up to three injections 
with collagenase. 
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At present there are only two long-term follow-up studies available in which collage-
nase was used, one with 8 years follow-up, the other with 2 years (Watt 2010, Hurst 
2009,). The former study (Watt 2010) also used another definition of recurrence, i.e., 
it was defined as any degree of loss of extension as compared to full extension. If we 
apply this definition in our study, the recurrence rate for the MCP joint would be 21% 
in the LF group and 57% in the PNF group (p = 0.00). For the PIP joint rates are 21% 
for the LF group and 70% in the PNF group (p = 0.00). In Watt’s study, recurrence rate 
in the MCP joint was 68% and in the PIP joint 100% after 8 years. Recurrence rates of 
collagenase therapy at eight years are therefore comparable, if not worse compared to 
our PNF results after 5 years. 
In a study conducted by Hurst and Badalamente in 2007 the recurrence rate defined 
as a return of contracture of at least 20° in successfully treated joints was 19% after 2 
years. If we would apply this in our study, recurrence rates would be as follows. In the 
MCP joint, we reached “success” in 72.1% (132/183 joints). Recurrence rate would be 
5.3% (4 out of 76 joints) in the LF group and 21.8% (12/55 joints) in the PNF group 
after 5 years. In the PIP joint, we reached success in 34.3%. In the LF group, recur-
rence was 5.3% (1 of 19 joints showed recurrence), and in the PNF group, recurrence 
would be 23.5% (4 out of 17 joints). These results indicate that the recurrence rate 
after collagenase is considerably higher than after LF and PNF, even after a consider-
ably shorter follow-up period.
Age versus recurrence
As Hindocha et al pointed out in their study, an age of onset that is younger than 50 
years increases chances for recurrent disease (Hindocha 2004). To our knowledge, our 
study is the first that showed a general correlation between age and disease recurrence. 
Dupuytren’s diathesis
Our findings do not corroborate with those of many authors supporting the view that 
Dupuytren’s diasthesis is a risk factor for recurrence or extension. We were unable to 
find a statistically significant influence of f ifth digit involvement, early-onset, radial 
disease, familial predisposition, ectopic lesions, gender or comorbidities, such as dia-
betes and epilepsy, on the appearance of recurrence. 
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McFarlane reported 5-year results on limited fasciectomy with the open-palm tech-
nique, and was also unable to prove the effect of Hueston’s diathesis. This f inding, as 
well as the establishment of an effect of age on recurrence, suggests that his f indings 
are consistent with ours (McFarlane 1990). 
Patient satisfaction
Patient satisfaction was high for both PNF and LF treatments. Patients who had re-
ceived LF were at 5 years significantly more satisfied with their treatment than those 
with PNF. The outcomes were influenced in a negative way when recurrence took 
place. However, many patients who suffered recurrent disease chose to undergo PNF 
again. This indicates that many patients are likely to prefer a minor procedure with 
fast recovery at the expense of a higher chance of an early recurrence.
Conclusions
Although PNF is equally effective for mild to moderate Dupuytren’s disease (Tubiana I 
and II), as we have shown in previous studies, recurrence rates are significantly higher 
than after LF. A higher age at disease presentation correlates with less tendency to 
recurrence. For this reason, we believe that PNF treatment is best suitable for well-
informed elderly patients with relatively mild contractures (Tubiana I and II) and 
for those who are willing to accept a higher recurrence risk in the context of a lower 
complication rate, fast recovery and minimal invasiveness.
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ABSTRACT
Purpose:  The increasing armamentarium to treat Dupuytren’s Disease includes percu-
taneous needle fasciotomy (PNF), a minimally invasive technique, which has proven to 
be effective for the treatment of primary disease.  We were unable to find reports on 
its effectiveness and long-term outcome in recurrent Dupuytren’s disease.  This study 
aims to fil l  this gap.
Methods:  30 patients with recurrent disease in 40 rays were studied, with a mean 
follow-up period of 4.4 years. Primary outcome measures were Total Passive Extension 
Deficit (TPED) reduction, and interval to a second recurrence, defined as an increase 
of more than 30o compared to the result at the end of previous treatment. Complica-
tions were noted.
Results:  TPED reduction was 76%. PNF was especially effective for the MCP joint, 
with an average reduction of 93%, whereas average reduction in the PIP joint was 
57%. Fifty percent of cases did not develop a secondary recurrence during follow-up.  
The other fifty percent of patients did, and recurrence was treated within 1.4 years 
on average after PNF. By means of PNF, tertiary treatment was postponed on average 
2.9 years starting from the initial treatment for Dupuytren’s disease. All secondary 
recurrences were successfully treated by limited fasciectomy, according to the patients’ 
wish. No major adverse effects were noted.
Conclusions:  PNF can effectively be applied for recurrent disease and 50% of cases re-
main free of recurrence for a mean of 4.4 yrs. If a secondary recurrence occurs, it does 
so relatively early after treatment: patients must therefore be willing to accept this 
uncertainty in the context of the advantages of PNF, such as fast recovery, low compli-
cation rate and minimal invasiveness.
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INTRODUCTION
Dupuytren’s Disease is an incurable chronic condition leading to finger contractures 
in most of the cases. Following surgical treatment fibromatosis generally recurs or ex-
tends and causes recontracture (Millesi 1981). Several risk factors have been suggested 
to influence the interval to, and severity of recurrence (Hueston 1984, Hindocha 2006, 
Abe 2004, Van Rijssen 2012a). These are onset of the disease before the age of 40, fa-
milial predisposition, presence of ectopic lesions, bilateral disease, radial involvement 
and fifth digit involvement.
Reported recurrence rates vary from 0-73% for limited fasciectomy (LF) (Van Rijssen 
2012, Foucher 2001, Jurisic 2008), to 20-100% for collagenase injections (Hurst 2009, 
Watt 2010), 50-85% for percutaneous needle faciotomy (PNF) (Van Rijssen 2012a, 
Badois 1993,Van Rijssen 2006a, Van Rijssen 2012b) and 8.4-47 % for dermofasciec-
tomy (Armstrong 200, Kelly 1992). The reason why these figures vary so largely is the 
lack of standard definitions for recurrence, and varying follow-up periods. One of 
the few available randomized controlled studies showed PNF and LF to be similarly 
effective for contracture release in lower Tubiana stages, and recovery following PNF 
much faster than after LF, but also that the recurrence rate 5 years after PNF is four 
times higher as compared to LF (Van Rijssen 2012a, Van Rijssen 2006 b). Despite these 
differences, many patients stil l  prefer PNF over LF because it is minimally invasive 
and has a short recovery period. Also for recurrent disease, many patients choose PNF 
treatment.
Studies with a reasonable follow up period that look into the efficacy and durability 
of treatment for recurrent disease are lacking. It has been reported that surgery for 
recurrences is more difficult and hampered by more complications than treating the 
first disease episode (Coert 2006). The aim of the present study was to investigate the 
effectiveness of PNF for the treatment of recurrent Dupuytren’s disease, to search for 
influences of known risk factors on the development of recurrences, and to investi-
gate the amount of time gained by performing PNF before further treatment becomes 
advisable.
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METHODS
We retrospectively reviewed all the patients included in our previous RCT on PNF 
versus LF, who developed recurrence during the 5-year follow-up period (Van Rijssen 
2012a). IRB approval was not obtained, as this is not required in our centre for this 
type of research. 
In 45 hands treated by PNF an increase of the Total Passive Extension Deficit (TPED) 
of at least 30o in one or more rays was found: this was our definition of recurrent dis-
ease. Twenty-six patients (26 hands) in the PNF group requested PNF for treatment of 
their recurrent disease, while 7 requested LF. The remaining 12 patients refused treat-
ment for their recurrences. In the group initially treated with LF, 4 out of 10 patients, 
(4 hands) wanted treatment for their recurrent disease by PNF.
In this study we specifically focused on these 30 patients who underwent PNF for their 
recurrent contracture following prior successful treatment with PNF (n=26 patients, 
26 hands) and LF (n=4 patients, 4 hands). Patients were treated in an outpatient set-
ting under local anaesthesia. The cord responsible for the f lexion contracture of the 
ray was sectioned at as many levels as possible in the palm and finger, depending on 
the location and extent of the disease, using a 25 Gauge needle mounted on an 10ml 
syringe. After division of the cord, the affected finger was passively extended to pull 
the ends of the sectioned cord apart and to obtain maximal release of the contracture. 
A small dressing was applied for 24 hours.  For a more detailed description of PNF, we 
refer to our previous study (Van Rijssen 2006b), and to the article on PNF by Eaton 
(Eaton 2011).  
Patients did not receive any specific post-operative hand therapy regimen or splint 
therapy.
We looked at the effects of PNF for recurrent disease, investigated whether secondary 
treatment sufficed or tertiary treatment was necessary, and if so, after how long.  We 
also compared the patient groups requiring second and third treatment with respect to 
differences in known risk factors for developing recurrences. Patient demographics are 
outlined in Table 1.
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Table 1: Patient characteristics
Statistical analysis was performed using SPSS version 15.0 (SPSS software, SPSS Inc. 
Chicago, IL). The chi square test was used for categorical data. The student’s t-test was 
used for the calculation of recurrence rate. Significance was set at p < 0.05.
RESULTS
Preoperative TPED was 50° (SD 21). Forty rays were treated: 4 middle fingers, 15 ring 
fingers and 21 small digits. These involved 23 rays in Tubiana stage I, 16 in Tubiana 
stage II, and one ray was classified as stage III according to the Tubiana system (Tu-
biana 1999). See table 2.
Table 2: The Tubiana Classification of Dupuytren’s Contracture of the Fingers
Tubiana I   = TPED of 0-45° 
Tubiana II   = TPED of 46-90° 
Tubiana III    = TPED of 91-135° 
Tubiana IV   = TPED of  > 135º
Number of patients (and percentage)
Gender Male 22 (73%)
Female 8 (17%)
Mean age (yrs) at time of 2nd PNF 59 
Ectopic Disease 9 (30%)
Positive family history for DD 12 (40%)
Associated Diseases (Epilepsy, Diabetes) 6 (20%)
Early-onset disease before 50 13 (43%)
Abe’s diasthesis (>4) 6 (20%)
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Thirty MCP joint contractures were treated and 22 PIP joint contractures. See table 3. 
Table 3: Contractures by joint
There was no significant preoperative difference in TPED in the initially LF or PNF 
treated groups, p= 0.406. The postoperative measurements of six patients were un-
available; only data on the necessity of their further treatment were present in these 
cases. In the other 24 cases, the mean remaining TPED after treatment was 13.1° (SD 
17.4). These 24 patients were treated in 32 rays, of which 14 MCP joints were treated, 
10 PIP joints, and 8 in both joints. 
Contracture reduction following PNF was 76%, (SD 34.4). Again, there was no differ-
ence in TPED reduction, regardless whether patients were previously treated with PNF 
or LF (p = 0.331). Average passive extension deficit (PED) reduction in the MCP joint 
was 93%, whereas in the PIP joint it was 57%.  The difference between PIP and MCP 
joints was statistically significant (p =0.000). 
No serious adverse effects such as nerve injuries or f lexor tendon injuries occurred. 
Skin fissures did occur, but none of them needed intervention.
The average follow-up of our patients was 4.4 years after PNF (SD 1.5; minimum 2, 
maximum 7 years). Of the 30 patients who underwent secondary PNF, 15 developed a 
contracture again and requested tertiary treatment (50% recurrence rate). Of the 24 
patients from whom we had a complete data set, 11 developed a recontracture (46%).  
All were treated by LF. This modality was the choice of the patient after having been 
informed about the longer disease free interval of LF (15). LF was performed between 
0.3-4 years, with an average of 1.4 year after the second PNF procedure (SD 1.9). Since 
the average time to the first recurrence had been 1.5 years, the secondary PNF treat-
ment postponed LF 2.9 years on average. 
MCP PIP MCP + PIP
No. 21 13 9
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We found no statistical differences in the distribution of known risk factors between 
the patient group requiring secondary treatment, and the patients who also received 
tertiary treatment. Age, ectopic disease and associated conditions, f ifth digit involve-
ment and age at onset of disease, did not seem to influence the development of recur-
rences (Abe 2004). Moreover, in this study, we could not demonstrate that the severity 
of PIP joint disease influenced the recurrence rate: p= 0.204. We were unable to find 
any differences in the outcomes between patients who previously received PNF or LF, 
most likely because the LF group was too small to allow statistical comparison.
DISCUSSION
This study aimed to investigate the short and long term effectiveness of PNF for 
recurrent DD and is the first of its kind.  PNF as a treatment modality for recurrent 
disease resulted in an initial 76% reduction of TPED.  PNF was especially effective 
for the MCP joint, with an average reduction of 93%.  Fifty percent of the patients did 
not need any further treatment during the course of this study. However, after a mean 
follow-up of 4.4 years, the other 50% did require additional treatment. No known risk 
factors were found to influence the development of a second recurrence. The third 
treatment for all secondary recurrences was LF, which was performed on average 1.4 
years after the second treatment. 
Our reduction of TPED as a result of the second PNF was larger than we reported in 
our previous study on primary disease (Van Rijssen 2006a, Van Rijssen 2006b). We 
suggest this is partly caused by 
1) The fact that preoperative measurements showed that contractures were slightly less 
severe than in the previous study, but most importantly :
2) We observed increased experience in our application and execution of the surgical 
technique, and dared to go more distal into the finger, which enabled us to gain better 
results.
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The same arguments may apply to the lower recurrence rate. In one of our previous 
studies, we found 84.9 % recurrences after 5 years follow-up, compared to the current 
rate of 50% now after 4.4 years (Van Rijssen 2012a). Also, our direct results in both 
MCP joints as well as PIP joints were better than those previously reported by us. 
We were unable to prove any influences of known risk factors on the occurrence of 
secondary recurrence, which is most likely explained by the fact that the sample size is 
relatively small. 
We were unable to find any reports on PNF for recurrent disease, and therefore we 
cannot put our results in perspective of other researchers. 
In a previous study, we proved that advanced age had an inhibitory effect on the ap-
pearance of recurrent disease (Van Rijssen 2006a). In the present study, this could not 
be reconfirmed. This is probably again caused by the fact that our study group was 
much smaller this time.
Our findings do not corroborate with those of many authors supporting the view that 
Dupuytren’s diasthesis is a risk factor for recurrence or extension. We were unable to 
find a statistically significant influence of f ifth digit involvement, early-onset, radial 
disease, familial predisposition, ectopic lesions, gender or co morbidities, such as dia-
betes and epilepsy, on the appearance of recurrences.  In our study on the long-term 
effects of PNF and LF, we could not prove the influence of these risk factors either 
(Van Rijssen 2012a). McFarlane reported 5-year results on LF with the open-palm 
technique, and was also unable to prove the effect of Hueston’s diathesis (McFarlane 
1990). These findings are consistent with ours. 
From the present study, we conclude that for both post-PNF and post-LF recurrences 
PNF leads to good immediate results. Secondary recurrences cannot be prevented and 
occur in 50% of cases after 4.4 years on average. These patients received a more inva-
sive treatment modality, which was LF in all patients. Using PNF for treatment of the 
first recurrence, this procedure was postponed for 2.9 yrs.  We found LF as a tertiary 
procedure not more complicated than in case of primary disease. However, the cords 
seem to be a bit broader and more diffuse than in primary disease. 
These findings suggest that PNF is a valuable treatment method for patients with re-
current Dupuytren’s disease.  
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ABSTRACT
Objective:  Several different surgical procedures have been used to treat Dupuytren’s 
contracture, but only few studies have compared recurrence following contracture cor-
rection achieved with different interventions.
Methods:  This study assessed definitions and rates of contracture correction and 
recurrence in patients undergoing surgical treatment of Dupuytren’s contracture. A 
literature search was carried out in January 2011 using the terms “dupuytren’s” AND 
(“fasciectomy” OR “fasciotomy” OR “dermofasciectomy” OR “aponeurotomy” OR “apo-
neurectomy”) and limited to studies in English. 
Results:  The search returned 218 papers, of which 21 had definitions, quantita-
tive results for contracture correction and recurrence, and a sample size of at least 
20 patients. Definitions for correction of contracture and recurrence varied greatly 
among papers and were almost always qualitative. Percentage of patients who achieved 
correction of contracture (i.e.,  responder rate) when evaluated at various times after 
completion of surgery ranged from 15% to 96.2%. Recurrence rates ranged from 4.9% 
to 73%. Review of these studies underscored the difficulty involved in comparing cor-
rection of contracture and recurrence rates for different surgical interventions because 
of differences in definition and duration of follow-up. 
Conclusions:  Clearly defined objective definitions for correction of contracture and 
for recurrence is needed for more meaningful comparisons of results achieved with 
different surgical interventions.
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INTRODUCTION
Dupuytren’s contracture is a f ibroproliferative disorder characterized by development 
of nodules and collagen cords within the palmar fascia of the hand that may shorten 
and cause progressive digital f lexion deformity (Bobinski 2008, Townley 2006). The 
overall prevalence of Dupuytren’s contracture is uncertain but is believed to range 
from 0.2% to 56% (Bayat 2007a, Hindocha 2009).
Diagnosis of Dupuytren’s contracture is based on a focused medical history and physi-
cal examination, with family history, risk factors (e.g. smoking and alcohol consump-
tion), and associated diseases (e.g.,  diabetes mellitus, liver disease, epilepsy) often tak-
en into consideration. The most common presenting feature early in the course of the 
disease is the appearance of a solid painless nodule in the palm. In addition, about 5% 
of patients complain of local tenderness (Bayat 2007a). Dupuytren’s contracture mani-
fests bilaterally in many patients (but not necessarily in the same stage), and there is 
no firm relation to handedness. The most commonly affected digits are the ring and 
little f inger, followed by the thumb, middle finger, and index finger. Dupuytren’s con-
tracture may also be associated with ectopic lesions, including Garrod’s knuckle pads, 
Peyronie’s disease, and Ledderhose’s disease (Bayat 2007a, Trojian 2007, Dohlen 1996). 
Currently, there is no “cure” for Dupuytren’s contracture, and it is generally believed 
that the condition does not resolve spontaneously (Bayat 2006b). Nonsurgical treat-
ments for Dupuytren’s contracture include splinting, physiotherapy, radiotherapy, oral 
vitamin E, and intralesional steroid injections (Bayat 2006b, Rayan 2008). Injectable 
collagenase clostridium histolyticum (CCH) has also been used to treat Dupuytren’s 
contracture and has been shown to be significantly superior to placebo in clinical tri-
als (Hurst 2009, Gilpin 2010). 
While nonsurgical interventions can be employed in patients with Dupuytren’s con-
tracture, surgery is stil l  the most common intervention. Procedures include dermo-
fasciectomy, standard limited fasciectomy, segmental fasciectomy, radical fasciectomy, 
open fasciotomy, and percutaneous needle fasciotomy (needle aponeurotomy) (Trojian 
2007, Bayat 2006b, Rayan 2008, Frank 2001, McGrouther 2005, Moermans 1991). 
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Treatment outcomes for patients who undergo surgery for treatment of Dupuytren’s 
contracture can be considered in 4 broad categories: initial response, risks for short- 
and long-term complications, and risk for recurrence (Benson 1998, Anwar 2007). 
Recurrence is relatively common in patients treated for Dupuytren’s contracture, and 
rational selection of therapy depends on understanding the risk for this outcome with 
different interventions (Watson 1991). This systematic review provides information 
about the success of different surgical approaches to the treatment of Dupuytren’s 
contracture, focusing on recurrence and considering the various criteria used to define 
successful treatment and recurrence.
METHODS
Collection of Publications 
On January 17, 2011, a PubMed literature search was carried out using the terms “du-
puytren’s” AND (“fasciectomy” OR “fasciotomy” OR “dermofasciectomy” OR “aponeu-
rotomy” OR “aponeurectomy”) and limited to studies in English. No other limitations 
were placed on this search except that case studies reporting results for fewer than 20 
patients were excluded. This search returned 218 papers (Appendix 1).
A total of 90 papers were eliminated since review of abstracts indicated that they did 
not contain any primary data regarding the use of a specific intervention and out-
comes (initial correction of contracture or recurrence). The 128 papers remaining 
after this step are listed in Appendix 2. Full text of the remaining 128 papers was ob-
tained and reviewed. During this review, studies were eliminated if there were results 
from fewer than 20 patients or if studies did not provide a description of the surgical 
procedure used, definitions for both correction of contracture and recurrence, and 
quantitative results for both of these outcomes. This resulted in a total of 21 studies 
that were included in the analysis. The following measures were tabulated for each 
of the remaining studies (note that not every study had information for each of the 
variables): number of patients, demographics (sex, age), clinical characteristics, type 
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of treatment, definition of correction of contracture and time when assessed, percent-
age of patients with correction of contracture, definition of recurrence and duration 
of follow-up, and percentage of patients with recurrence. For evaluation, studies were 
grouped into 2 categories with respect to surgical intervention: fasciectomy (including 
aponeurectomy) and fasciotomy.
RESULTS
Results from this analysis, including the number and characteristics of the patients 
treated, study design and surgical procedure, definitions for correction of contracture 
and recurrence, correction rate (i.e.,  percentage of patients meeting the criteria for 
initial treatment success), duration of follow-up, and recurrence rate are summarized 
in Tables 1 and 2 for the two major classes of surgical procedures carried out. Eigh-
teen of the studies used some variation of fasciectomy (Table 1), and 3 studies used 
fasciotomy (Table 2). Sixteen of the papers were descriptions of case series, 2 were 
randomized clinical trials, 1 was a prospective single-treatment study, 1 was a non-
randomized clinical trial,  and 1 was a survey.
Correction of contracture was defined both quantitatively and qualitatively in the 
studies reviewed (Tables 1 and 2), but all analyses presented results as percentages of 
patients who met the stated criteria for correction (i.e.,  responder frequency). These 
ranged from 15% to 96.2%. However, it is very difficult to compare results from dif-
ferent trials because of the wide range of definitions for correction of contracture that 
were employed as well as differences in the times at which the initial outcome of the 
surgical procedure was assessed. Timing of evaluation was particularly varied and ex-
tended from 2–3 weeks to 2.5 years after the procedure (Anwar 2007, DeMaglio 1996). 
Detailed quantitative criteria for correction of contracture and timing of assessments 
were provided in only a few studies (Ullah 2009, Citron 2003b). 
There was also great variability in how the studies defined recurrence and a corre-
spondingly wide range of recurrence rates. Definitions of recurrence were qualitative 
in 20 of the 21 studies reviewed (95.2%). All of the qualitative definitions of recur-
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rence can be paraphrased as “occurrence of the evidence of disease in the area of the 
operation.” The single quantitative definition of recurrence was total passive extension 
deficit increase of ≥30° during follow-up compared with the immediate postopera-
tive measurements (Van Rijssen 2006a). Another source of variability in assessment of 
recurrence is the wide range of follow-up durations in the studies reviewed (12 months 
to 10 years) (Anwar 2007, Kartik 1963). Recurrence rates ranged from 4.9% to 73% 
(Kartik 1963, Van Rijssen 2006b).
DISCUSSION
The results from this systematic review of the current literature underscore the dif-
ficulties in comparing the initial effectiveness and risk for recurrence of different 
surgical interventions in patients with Dupuytren’s contracture. Definitions of both 
correction of contracture and recurrence are variable, and the time at which these 
outcomes are evaluated differ greatly from one study to another. This is largely due 
to the fact that the studies reviewed were not aimed at providing information about 
the comparative efficacy of different surgical procedures for Dupuytren’s contracture. 
Rather, they were retrospective evaluations of outcomes for a given procedure carried 
out by one surgeon or at a single center. Such studies have a very different goal from 
randomized controlled clinical trials and generally do not include information about 
patient inclusion/exclusion criteria, an a priori definition of endpoints, or timing 
of evaluations. Interpretation of case reviews of a series of patients being managed 
with a single procedure is also limited by the possibility that results may be biased by 
inclusion of patients likely to have good outcomes from that intervention based on the 
investigator’s past experience (Hess 2004). Moreover, all of the surgical interventions 
assessed in this review appear to be more effective than no treatment, and placebo-
controlled studies of these established procedures would provide little useful informa-
tion. Controlled comparative studies would be difficult because of the need to stan-
dardize the surgical interventions being evaluated across multiple physicians, centers, 
and patients. 
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Ideally, surgical interventions for Dupuytren’s contracture should be assessed in large-
scale, randomized, double-blind, controlled clinical trials with well-defined patient 
populations and time points for evaluation. Double blinding is almost impossible in 
studies that compare surgical interventions for the correction of Dupuytren’s contrac-
ture. It has been accomplished in randomized, double-blind placebo-controlled studies 
of injection of CCH for the treatment of Dupuytren’s contracture (Hurst 2009, Gilpin 
2010). Additionally, these studies also carefully and quantitatively defined the entry 
criteria for the trial.  Patients had fixed-f lexion contractures of the metacarpophalan-
geal (MCP) or proximal interphalangeal joint (PIP) ≥20° in one finger (excluding the 
thumb). They had MCP joint contractures of 20° to 100° or PIP joint contractures of 
20° to 80° and were unable to simultaneously place the affected finger and palm f lat on 
a table (Hurst 2009, Gilpin 2010). 
Comparison of surgical treatments for Dupuytren’s contracture could also be facili-
tated by consistent and quantitative definitions of both correction of contracture and 
recurrence. The definitions for both correction of contracture and recurrence were 
qualitative in all but a few of the studies included in this review (Tables 1 and 2). The 
most detailed definition for correction of contracture in the studies reviewed was: 
good correction if ≤15° loss of extension remained after treatment for either the MCP 
or the PIP joint and f lexion to the palm was complete; fair if there was 15° to 25° loss 
of extension and the patient could f lex to within 1 cm of the distal palmar crease; and 
poor if the patient had greater loss of f lexion or extension (Gelberman 1980). More 
often, correction of contracture was defined qualitatively as clearance of disease, 
freedom from disease, or full correction of contracture (Hueston 1963, Rombouts 
1989, Dias 2006). A detailed quantitative definition of correction of contracture was 
employed in the phase 3 studies of CCH for the treatment of Dupuytren’s contracture. 
In these studies, correction of contracture was defined as a reduction in primary joint 
contracture to 0° to 5° of full extension 30 days after the last injection. Presentation 
of results from these trials also included mean changes in range of motion for injected 
joints at 30 days after the last injection (Hurst 2009, Gilpin 2010). Definitions of 
recurrence in most of the studies reviewed were also qualitative. Examples include ap-
pearance of new Dupuytren’s tissue within the area cleared at operation, reappearance 
of Dupuytren’s disease in the cleared operative field, and the appearance of new fascial 
bands, determined by appearance and palpation, in an area where fasciectomy had 
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been previously performed (Hueston 2009, Nieminen 1986, Gelberman 1980). Com-
parison of the long-term efficacy of different treatments for Dupuytren’s contracture 
would be facilitated by a quantitative definition of recurrence of the type employed 
in the phase 3 studies of CCH injection. In these trials, recurrence of contracture was 
defined as an increase in joint contracture to ≥20° in the presence of a palpable cord 
at any time during the study in primary joints that reached the criterion for correction 
of contracture (Hurst 2009, Gilpin 2010). An earlier study of CCH injection for the 
treatment of Dupuyten’s contracture also employed the ≥20o definition of recurrence 
(Badalamente 2007). 
Van Rijssen and colleagues have also used a quantitative definition (total passive 
extension deficit [TPED] increase of ≥30° compared with immediate postoperative 
measurements) to assess recurrence following percutaneous needle fasciotomy (Van 
Rijssen 2006a). A soon to be published five-year follow up of a randomized clinical 
trial comparing percutaneous needle fasciotomy and limited fasciectomy will also pro-
vide further insight into response to surgery and recurrence by using specific defini-
tions for assessment of these parameters (Van Rijssen 2011b). 
An important question that remains to be answered is what is the best approach to 
study interventions aimed at correcting Dupuytren’s contracture? Assessments of CCH 
injection for the treatment of this condition and the upcoming comparative van Rijs-
sen data may provide some guidance for changes (Hurst 2009, Gilpin 2010, Badala-
mente 2007, Van Rijssen 2011b). Becker and Davis have also suggested that objective 
measures for correction of contracture, well-defined follow-up intervals, and a con-
sensus definition of recurrence be employed in studies of treatments for Dupuytren’s 
contracture (Becker 2010). 
In conclusion, results from the present analysis indicate high variability in the defini-
tion of both correction of contracture and recurrence and a corresponding wide range 
of outcomes reported in studies of surgical interventions for Dupuytren’s contracture. 
Randomized controlled clinical trials provide the best approach to comparison of 
treatments but are difficult to carry out for this condition. At a minimum, develop-
ment of consensus endpoints and approaches to follow-up of patients undergoing 
specific treatments may facilitate evidence-based recommendations for treatment of 
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Dupuytren’s contracture. The detailed definitions for correction of contracture and 
recurrence and clear definition of timing for patient evaluations in clinical studies of 
CCH for the treatment of Dupuytren’s contracture provide a good example of how this 
can be accomplished (Hurst 2009, Gilpin 2010).
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168 Summary and general discussion
This thesis was primarily designed to compare limited fasciectomy (LF) to percuta-
neous needle fasciotomy (PNF) as treatment modalities for Dupuytren’s Disease in a 
randomised fashion. The effect of these two treatments on the total passive extension 
deficit (TPED) was compared together with their complication rates, recurrence rates 
and overall patient satisfaction. Furthermore, we studied the effects of PNF for recur-
rent disease and performed a literature study on definitions of successful treatment 
and recurrence in Dupuytren’s disease.
Chapter one  is an introduction to the subject, defines the aims of the thesis and gives 
an outline.
Chapter two  gives, based on the available literature by the time it was written, an 
overview of different treatment modalities for Dupuytren’s disease. One of the most 
important conclusions is that, although more and more treatment options seem to be 
available, very few comparative studies have been published. 
In chapter three ,  the results of a pilot study on percutaneous needle fasciotomy are 
presented. This study was designed to determine whether in our hands, PNF was an 
effective treatment for Dupuytren’s disease, and if results were comparable to those 
reported by others. For this purpose, the results of 74 consecutive percutaneous needle 
fasciotomies for Dupuytren’s contracture were studied. Pre-operative and postopera-
tive total passive extension deficit was measured. Patients were seen at the outpatient 
clinic after a mean of 33 months for final follow-up. Extension deficit and sensibil-
ity were measured and f lexor tendon function assessed. Recurrence, defined as an 
increase of 30º of TPED or more compared to the immediate postoperative measure-
ment, and complications were also noted. Immediate outcome was excellent with an 
average improvement of 77%. After 32 months, we were able to review 55 rays (74%). 
The recurrence rate was 65%. Two patients experienced a slightly diminished sensi-
bility on one side of the finger. There were no f lexor tendon injuries and full active 
f lexion in all treated digits was possible. Comparison to other studies showed that our 
immediate results were very good, and recurrence rates were comparable to those of 
other authors. 
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Chapter four  is the first chapter that extensively describes the design and implemen-
tation and short-term (six weeks) outcome of our randomized controlled study on 
percutaneous needle fasciotomy versus limited fasciectomy.
This randomized controlled trial was designed to compare percutaneous needle 
fasciotomy (PNF) with limited fasciectomy (LF) with regard to outcome, number of 
complications, recovery, and patient satisfaction.
One hundred and sixty-six rays of 117 hands in 113 patients were treated: 88 by PNF 
and 78 by LF. Total passive extension deficit (TPED) improvement at 1 week and at 6 
weeks following treatment were the primary outcome parameters; patient satisfaction, 
hand-function recovery, and complication rate were secondary outcome parameters. 
The Disabilities of the Arm, Shoulder, and Hand questionnaire (DASH) was used to 
measure disabilities of the upper extremity before and after treatment and all adverse 
effects and complications were recorded.
Overall TPED improvement was greatest at 6 weeks. In the PNF group TPED improved 
by 63% versus 79% in the LF group; this difference was statistically significant. These 
results were comparable to those reported by others. Results at the proximal interpha-
langeal joint were worse than those at the metacarpophalangeal and distal interpha-
langeal joints for both the PNF and LF groups. The rays classified before surgery as 
Tubiana Stages I and II showed no difference between these treatments, but for rays 
higher than Stage II LF clearly was superior to PNF as a treatment modality. The rate 
of major complications in the LF group was 5% (one nerve injury) versus 0% in the 
PNF group. Patient satisfaction was almost equal but direct hand function after treat-
ment was considerably better in the PNF group, and the degree of discomfort that PNF 
treated patients experienced was lower. This was underscored by the Disabilities of 
the Arm, Shoulder, and Hand scores in the PNF group, which were significantly lower 
than those in the LF group at all time points measured.
From this study it was concluded that in cases with a TPED of 90° or less PNF is in the 
short run a good treatment alternative to LF for treatment of Dupuytren’s disease. This 
study was the start of an exciting study with five years follow-up.
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In chapter five ,  the 3-years follow-up results of the randomized clinical trial are 
presented. In this study we focussed primarily on recurrence, defined as an increase 
in TPED of at least 30o as compared to the six weeks results. This interim analysis 
was planned to be able to compare especially the PNF results with those previously 
reported (Foucher 1992, Van Rijssen 2006a).
A total of 115 hands in 111 patients were available for follow-up at 3 years (8 patients 
with 8 hands were lost to follow-up). This intermediate analysis revealed a recurrence 
after PNF in 64% of cases. These results were comparable to those of the authors just 
mentioned. Recurrence after PNF occurred significantly more frequent (p=0.005) than 
after LF (9%). We also found that younger patients develop recurrent disease sooner 
after treatment for Dupuytren’s disease, independent of the treatment they received. 
Satisfaction with the results of treatment was high in both groups, but in the LF group 
higher than in the PNF group. Nevertheless, patients who had previously undergone 
PNF and developed recurrence were keen to have their recurrences treated by PNF 
again. 
Chapter six  delineates the 5-year results of the study. From the population of patients 
described in Chapters 3 and 4, 93 patients with 96 affected hands were stil l  available 
for study. After 5 years, the recurrence rate in the PNF group was with 84.9% again 
significantly higher than that of the LF group (20.9%), p < 0.001, and occurred signifi-
cantly sooner in the PNF group (p = 0.001). Higher age at time of treatment was again 
found to diminish the risk of recurrent disease, p=0.005. We were unable to prove that 
diathesis characteristics influenced recurrence. Satisfaction was high in both groups, 
but in the LF group significantly higher than in the PNF group. Nevertheless, many 
patients (53%) chose to have their recurrence treated by PNF.
Comparison of the results on PNF and LF with available results of treatment with 
Clostridium Histolyticum derived Collagenase revealed that we achieved better long 
term results with LF than were obtained with collagenase (Hurst 2007, Hurst 2009, 
Watt 2010). A single treatment with PNF, however, seems to be somewhat inferior to 
up to three injections with collagenase. Recurrence rates of collagenase therapy are 
comparable, if not worse compared to our PNF results after 5 years. 
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The graph below shows the number of hands in the study at commencement,  
at 6 weeks, 3 years and 5 years.
Graph 1: Number of hands in the study at the start, after 6 weeks, 3 years and at 5 
years.
 
Chapter seven  is the first publication of results of PNF for recurrent disease. 
From the previous studies, 30 patients with recurrent disease, with a total of 40 af-
fected rays in 30 hands, were studied. The mean follow-up (FU) was 4.4 years. Primary 
outcome measure were Total Passive Extension Deficit Reduction, and interval to a 
second recurrence, defined as an increase of more than 30o compared to the result at 
the end of previous treatment. 
Immediate results were good: TPED reduction was 76%. PNF was especially effective 
for the MCP joint, with an average reduction of 93%, whereas average reduction in 
the PIP joint was 57%. Fifty percent of cases did not develop a secondary recurrence 
during follow-up.  The other fifty percent of patients did, and recurrence was treated 
within 1.4 years on average after PNF. By means of PNF, LF was postponed on average 
2.9 years starting from the initial treatment for Dupuytren’s disease. 
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From this study we concluded that PNF can effectively be applied for recurrent disease 
and 50% of cases remain free of recurrence for a mean of 4.4 yrs. If a secondary recur-
rence occurs, it does so relatively early after treatment: patients must therefore be 
willing to accept this uncertainty in the context of the advantages of PNF, such as fast 
recovery, low complication rate and minimal invasiveness.
Chapter eight  concerns a systematic review about the success of different surgical 
approaches to the treatment of Dupuytren’s contracture, focusing on recurrence and 
considering the various criteria used to define successful treatment and recurrence.
A literature search was carried out in January 2011 using the terms “dupuytren’s” AND 
(“fasciectomy” OR “fasciotomy” OR “dermofasciectomy” OR “aponeurotomy” OR “apo-
neurectomy”) and limited to studies in English. 
The search returned 218 papers, of which 21 had definitions, quantitative results 
for contracture correction and recurrence, and a sample size of at least 20 patients. 
Definitions for correction of contracture and recurrence varied greatly among papers 
and were almost always qualitative. Percentage of patients who achieved correction 
of contracture (i.e.,  responder rate) when evaluated at various times after comple-
tion of surgery ranged from 15% to 96.2%. Recurrence rates ranged from 4.9% to 73%. 
Review of these studies underscored the difficulty involved in comparing correction of 
contracture and recurrence rates for different surgical interventions because of differ-
ences in definition and duration of follow-up. 
This study showed us that clearly defined objective definitions for correction of con-
tracture and for recurrence are needed for more meaningful comparisons of results 
achieved with different surgical interventions. 
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Therefore, the principle conclusions from this thesis that compared the short and long 
term outcome of LF and PNF are that 
1. PNF is best suitable for elder patients and for those willing to accept the 
drawback of a possible early recurrence and want to benefit of advantages such as 
fast recovery, low complication rate and minimal invasiveness.
2. LF stil l  is a very reliable treatment modality, with major advantage that 
recurrences do not occur as rapidly as following PNF. Its major disadvantage is 
that it has a much longer rehabilitation period. Since recurrence is age-related, LF 
may be a better treatment choice for the younger age group.
3. PNF can also be attempted in case of recurrent disease. It will “cure” half of the 
patients, and at least postpones more invasive treatment regimens for the other 
half of patients.
Due to the fact that clearly defined definitions in literature on treatment of Dupuy-
tren’s disease are lacking, comparison between studies is difficult and less reliable than 
it possibly could be.
The strongholds of this research project were its randomised controlled nature and the 
fact that beforehand a pilot study was performed to find out if our treatment results 
were comparable to those of others. By doing all this we feel that we have contributed 
significantly to the evidence based scientific knowledge of treating patients with Du-
puytren’s Disease.
However, when looking back we also see a number of shortcomings and mistakes of 
this project, which we want to spell out in detail to help successors in the design of 
future studies.
Randomisation
Patients were randomised in the two treatment groups by having a secretary at ran-
dom pull a sealed envelop containing a note saying either LF or PNF from a box. In a 
review study by Becker and Davis this method was termed “pseudo-randomisation”. 
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Although we cannot agree with this term, for future studies we will use a computer 
based randomisation method (Kang 2008, Becker and Davis 2011).
Treatment 
We were relatively inexperienced in the use of PNF when we embarked on this journey. 
Therefore we performed a pilot study to investigate if our results were comparable to 
those of others. And indeed these results were similar. Therefore we felt comfortable 
to start the RCT. Now, with almost 10 years of experience in PNF we have become a bit 
more daring and are not hesitant to apply PNF on cords in the vicinity of the neuro-
vascular bundles. We fully agree will Eaton (2011) that this is safe as long as only the 
skin is numbed. Our Tubiana 3 and 4 results these days are better than those of our 
RCT (unpublished data).
During the RCT we inflicted injury to a nerve during LF. It was the ulnar nerve of the 
long finger in a case in which only the ring finger was affected: the nerve was pulled 
up together with surrounding fat tissue that was stil l  connected to the cord. This in-
jury was an act of inattention and should have been prevented. 
Patient questionnaires
For the registration of events in the first 6 weeks after treatment in the RCT we asked 
all patients to fil l  out a Dutch translation of the DASH questionnaire and the Short 
Form (SF)-36. The Dutch translation of the DASH questionnaire is a validated in-
strument that can be used to score disabilities of the upper extremity during daily 
activities (Hunsaker, 2002 Veehof 2002). This questionnaire consists of 30 items that 
address disability and symptoms of the upper extremity on a scale from 0 to 5. The 
scores are added and transformed into a 100-point scale. The lower the score, the less 
disability is experienced. The SF-36 is a general health survey with 36 questions. Func-
tional health and well-being scores as well as psychometrically-based physical and 
mental health summary measures are taken. (Ware and Sherbourne 1992)  It consists 
of eight scaled scores, which are the weighted sums of the questions in their section. 
Each scale is directly transformed into a 0-100 scale.
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From the SF-36, it was already known in 1999 that response rates in patients above 65 
years old and in patients with cognitive or physical disabilities are too low to be used 
(Andresen 1999). When we designed our protocol we did not know this, but during 
the study we became bluntly aware of this shortcoming, since the answers the patients 
gave were inconsistent. In our study the mean age at commencement was 63 years old. 
In the description of our results, we decided to discard all data on the SF-36 because 
of the high rate of invalid fil led-out questionnaires.
In the DASH scoring system, at least 27 of 30 items must be scored to give a reliable 
outcome. The DASH score questionnaires at the start of the study and in the immedi-
ate postoperative period were fil led in satisfactory by most patients. However, as time 
progressed during the study, many patients appeared to be unwilling to fil l  out the 
long questionnaire over and over again. This resulted in too high failure rates, which 
made the DASH questionnaire useless. In 2006, the QuickDASH was developed. This 
is a much shorter questionnaire with reliable outcome in Dupuytren’s disease (Budd 
2011). If this had been available at the start of our study, this would have been a much 
better alternative. 
Another shortcoming of DASH is that it is not very specific for the investigations of 
hand problems. For future trials, alternatives worth considering are Patient Evaluation 
Measure (PEM), Michigan Hand outcomes Questionnaire (MHQ), Patient Rated Wrist/
Hand Evaluation (PRWHE) and the very recently presented Southhampton’s Dupuytren 
Scoring Scheme (Bindra 2003, Changulani 2008,Van de Ven-Stevens 2009,Warwick, 
recently submitted for publication 2011)
All patients were asked to fil l  in the questionnaires at home every week after the treat-
ment, until 6 weeks post-treatment. Two patients failed to fil l  in any questionnaires 
and for this reason we excluded them for further follow up. We now feel that this was 
unnecessary : we could have left them in the trial for longer-term follow up. 
Follow-up investigations
Most, but not all follow-up investigations were conducted by an independent inves-
tigator. In future studies this should always be done by a person not involved in the 
study.
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PNF for recurrent disease
Our study on PNF for recurrent disease is not of a f lawless design.  Obviously, the 
group of patients treated by PNF for recurrent disease we reviewed for our study on 
the application of PNF for recurrence was quite small (30 patients). This made it dif-
ficult to prove if any of the known risk factors had an influence on the timing of a 
second recurrence. Possibly, there was also a selection bias (patients were not ran-
domly assigned to either PNF or LF), which may have caused the outcomes of these 
patients to be more favourable. However, as this is the first study on the effectiveness 
and long-term outcome of PNF, we feel that it is stil l  very worthy of publication.
Definition of recurrent disease
As mentioned in all chapters on recurrence rates, “recurrence” is an il l-defined entity 
in Dupuytren’s disease. This makes comparison to previously reported studies almost 
impossible. The most commonly used definition is “reappearance of Dupuytren’s tis-
sue in a previously operated zone” (McFarlane 1990, Becker 2010).  This definition of 
recurrence could not be used in this study, since in PNF no tissue is removed. Nodules 
that are present before the procedure often remain unchanged or at best soften. The 
cords are divided but over time seem to reconnect. For this study we therefore used 
a more indirect definition for recurrence: an increase of the Total Passive Extension 
Deficit of 30º or more in a ray compared to the result at 6 weeks post treatment. This 
measure is reproducible and clinically more significant than the other definitions, 
since it is progressive contracture that ultimately leads to reintervention, while reap-
pearance of Dupuytren’s tissue itself does not necessarily impair hand function or 
forms the indication for treatment. We chose a worsening of digital extension of 30º 
because this corresponds to Hueston’s tabletop test and since it is the minimal con-
tracture that makes a patient eligible for surgery at our treatment centre.
However, many of the latest studies on Dupuytren’s disease, such as the ones on 
Clostridium Histolyticum derived Collagenase, use a very different definition (Hurst 
2009, Watt 2010, Gilpin 2010). All collagenase studies look at the effect of treatment 
at each joint individually. The treatment is named “clinically successful” when correc-
tion of the deformity is to within 0-5˚ of full extension. Up to three injections at 30 
9177Summary and general discussion
days’ intervals are allowed to reach this endpoint. We find this way of presenting data 
somewhat misleading. The treated MCP joint can remain good, while the PIP joint is 
contracting. This stil l  may impair the patient’s hand function, and that is what ulti-
mately defines the success of the treatment of Dupuytren’s disease. Therefore, it is our 
opinion that one should not look at one joint, but at least at a complete ray. Much can 
be said about looking at a whole hand altogether, because Dupuytren’s disease is a dif-
fuse disease that is not restricted by any imposed anatomic border. 
Moreover, in studies on recurrence after treatment with collagenase, only the “clini-
cally successfully” treated patients are taken into account in analyzing recurrence rates 
(Hurst 2009, Watt 2010, Xiaf lex press release 2011). This is obviously a deceiving way 
to present one’s achievement. For instance, in recently published data by Xiaf lex, only 
623 of 1568 treated joints reached clinical success (39,7%), 945 did not reach the ‘suc-
cess’ endpoint. After 3 years, 217 of former had recurrence. They present a recurrence 
rate of 39,7 % (217/623), while the recurrence rate of the other subgroup remains 
unknown, which obviously creates a bias.
In our study, all treated rays of one hand fell out of the study when one ray on this 
hand showed signs of recurrence to prevent bias. This is another shortcoming of our 
design: we could have followed each ray individually.
The issues on definitions of treatment success and recurrence bothered us very much, 
which urged us to write a review study on the subject. This review was performed in 
January 2011. We feel that if we would have considered these issues in more detail at 
the start of the randomized study, we might have made other choices, such as present-
ing our data in a different way to make comparison with for example collagenase stud-
ies easier.
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FUTURE PERSPECTIVES
It would be much more reliable if every study on Dupuytren’s disease would use the 
same definition of recurrence, which should be applicable to every treatment modality. 
We recommend using the following definition of recurrence: an increase of TPED of a 
f ixed number of degrees (20 or 30°) compared to the immediate postoperative mea-
surements in the ray previously treated. Extension should be defined as an increase 
of 20-30° TPED in a ray outside the area previously treated. This way, extension and 
recurrence are clinically relevant for the patient, for hand function deteriorates when 
Hueston’s tabletop test is positive. 
Many new exciting techniques are being developed in treatment of Dupuytren’s dis-
ease. Very recently, new work was published on a combination of extensive percuta-
neous aponeurotomy and lipografting (Hovius 2011). The authors found the results 
of regular aponeurotomy disappointing, due to early recurrences, and decided to add 
fat subcutaneously as interposition between skin and fascia, but also to restore the 
relative deficiency of subcutaneous fat. Short-term results are very promising: in 50 
patients who were treated, mean improvement ranged from 56.4% to 114%, and 88% of 
patients reached Tubiana stage I after treatment. It will be exciting to hear long-term 
results, which are not available at this moment.  
Also, many studies are being performed on treatment with collagenase (Badalamente 
2000, 2002, 2007, Hurst 2009, Watt 2010). It would be very interesting to compare col-
lagenase with other treatment regimens on Dupuytren’s Disease to see whether this is 
truly a good alternative. In the near future, more data will probably become available 
on long-term data en effectiveness. 
In Germany, radiotherapy is by some employed in early stage Dupuytren’s disease 
(Betz 2010). 
However, more research should be done, not only on effectiveness and safety of these 
techniques, but more importantly, to compare these treatment regiments in equal 
groups in a randomised controlled fashion. As said before, comparing current litera-
ture would be easier if the same definitions of recurrence and extension would be used 
in all studies. 
Interestingly, we were the first to prove that higher age at time of treatment diminish-
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es the risk of recurrent disease. No other studies have proven this before. It would be 
interesting to see whether this can be re-confirmed in larger studies as well,  and to see 
whether a different advice on treatment should be given to various age groups.  
Another unanswered question remains what the role is of postoperative hand therapy 
and splint therapy in the treatment of DD. Although routine splinting after fasciecto-
my and dermofaciectomy appears not to improve disability and range of motion, there 
might be a place for splinting and hand therapy after less-invasive treatments, such as 
PNF, collagenase, of radiotherapy (Meinel, unpublished data, Jerosch-Herold 2011).  
Last but not least, very little literature is available on treatment of recurrent disease, 
independent which technique is used.  Recurrences are very common, no matter which 
initial treatment modality is used. It would be very interesting to see which treatment, 
if any, is superior in treating recurrent disease, whether different age groups would 
have different results after treatment for recurrent disease and whether splinting or 
hand therapy would be of any benefit after recurrence treatment. 
We have proved that PNF is a well-worthy alternative in the treatment of recurrences. 
Further studies with larger groups of patients are needed to define its specific indica-
tions. And hopefully, we will be able to compare the results of PNF and other treat-
ment regimens for recurrent disease in the future.
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CHAPTER TEN: 
 
SAMENVATTING EN ALGEMENE DISCUSSIE
186 Samenvatting en algemene discussie
Het onderzoek dat is verzameld in dit proefschrift is er vooral op gericht om op ge-
randomiseerde wijze de selectieve fasciëctomie (SF) en de percutane naald fasciotomie 
(PNF) te vergelijken als behandelingsmethoden voor de ziekte van Dupuytren. Het 
effect van deze twee behandelingen op het totale passieve extensie deficit (TPED) werd 
vergeleken, evenals complicaties, recidief en de algemene tevredenheid van de patiënt 
op de korte, middellange (3 jaar) en lange (5 jaar) termijn. Voorts zijn de effecten van 
PNF onderzocht op het optreden van een recidief en is een tweetal literatuurstudies 
verricht. De eerste literatuurstudie geeft een resumé van de voors en tegens van alle 
beschikbare behandelingsmogelijkheden en de tweede bevat een systematische review 
van de definities van “succesvolle behandeling” en “recidief ” bij de ziekte van Dupuy-
tren. Het onderstaande geeft een samenvatting van de bevindingen, analyseert deze 
bevindingen kritisch en doet aanbevelingen voor toekomstig onderzoek naar de ziekte 
van Dupuytren.
Hoofdstuk één  omvat de inleiding op het onderwerp: in dit hoofdstuk worden de doel-
stellingen van het proefschrift beschreven. 
Hoofdstuk twee  geeft, op basis van de literatuur beschikbaar in 2008-9, een overzicht 
van de verschillende behandelingsmogelijkheden voor de ziekte van Dupuytren. Een 
van de belangrijkste conclusies is dat, hoewel steeds meer en meer behandelingsopties 
beschikbaar zijn, zeer weinig vergelijkende studies zijn gepubliceerd.
Hoofdstuk drie  presenteert de resultaten van de pilotstudy naar percutane naald fas-
ciotomie. 
Deze studie werd ontworpen om te laten zien dat wij in staat waren PNF op een effec-
tieve manier uit te voeren en dat de resultaten vergelijkbaar waren met die uit de lite-
ratuur. Hiervoor werden de resultaten van 74 opeenvolgende percutane naald fascio-
tomiën bestudeerd. Het preoperatieve en postoperatieve extensietekort werd gemeten. 
De patiënten werden poliklinisch gezien na een gemiddelde van 33 maanden voor de 
laatste follow-up. Verergering van het extensiedeficit werd gemeten, de sensibiliteit 
werd onderzocht en de f lexorpeesfunctie beoordeeld. Het ontstaan van een recidief, 
gedefinieerd als een toename van het extensiedeficit van 30 º of meer in vergelijking 
met de directe postoperatieve meting, werd genoteerd, evenals de eventuele compli-
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caties. Het onmiddellijke resultaat was uitstekend met een gemiddelde verbetering 
van het extensietekort van 77%. Na 32 maanden werden 55 stralen teruggezien voor 
follow-up (74%). Het recidiefpercentage was 65%. Twee patiënten ervoeren licht ver-
minderde unilaterale sensibiliteit.  Er waren geen buigpeesletsels en volledige actieve 
f lexie was mogelijk in alle behandelde vingers. Vergelijking met andere studies toonde 
aan dat onze directe resultaten zeer goed waren, en de recidiefkans in onze studie ver-
gelijkbaar was met die van andere auteurs.
Hoofdstuk vier  beschrijft uitgebreid het ontwerp, de uitvoering en de korte termijn 
resultaten (na zes weken) van de gerandomiseerde gecontroleerde vergelijkende studie 
naar percutane naald fasciotomie en selectieve fasciëctomie 
Honderd zesenzestig stralen van 117 handen in 113 patiënten werden behandeld: 88 
middels PNF en 78 middels SF. De verbetering van het extensiedeficit op 1 week en 6 
weken na de behandeling waren de belangrijkste uitkomstmaten, de tevredenheid van 
patiënten, het handfunctie herstel en het aantal complicaties zijn secundaire uitkomst 
parameters. De handicap van de arm, schouder en hand vragenlijst (DASH scorelijst) 
werd gebruikt om symptomen en functionele beperkingen in de bovenste extremiteit 
gedurende de week voorafgaand aan de behandeling te meten en na 1 en 6 weken na de 
behandeling. Alle bijwerkingen en complicaties werden geregistreerd.
Algehele verbetering van het extensietekort was het grootst na 6 weken. In de PNF 
groep verbeterde deze met 63% tegenover 79% in de SF-groep, dit verschil was sta-
tistisch significant. Deze resultaten waren vergelijkbaar met die welke door anderen 
werden gepubliceerd. Resultaten van de PIP gewrichten waren slechter dan die van de 
MCP en DIP gewrichten in zowel de PNF en SF groep. De stralen welke preoperatief 
geclassificeerd werden als Tubiana stadium I en II toonden geen verschil tussen deze 
behandelingen, maar voor stralen hoger dan stadium II was SF duidelijk superieur. In 
de SF-groep was de kans op ernstige complicaties 5% (één zenuwbeschadiging) versus 
0% in de PNF groep. De tevredenheid van patiënten was vrijwel gelijk, maar de directe 
handfunctie na de behandeling was aanzienlijk beter in de PNF groep, en de mate van 
ongemak welke met PNF behandelde patiënten ervoeren lag lager. Dit werd onder-
streept door de DASH scores in de PNF groep, die beduidend lager waren dan die in 
de SF-groep op elk gemeten tijdstip (behalve preoperatief ).
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Uit deze studie kan worden geconcludeerd dat in gevallen waarbij het extensietekort 
kleiner of gelijk is aan 90°, PNF een goede behandelingsalternatief is voor SF met 
betrekking het directe behandelresultaat. Deze studie was het begin van een onderzoek 
met vijf jaar follow-up.
In hoofdstuk vijf worden de 3-jaar follow-up resultaten van de gerandomiseerde kli-
nische studie gepresenteerd. In deze studie hebben we ons in de eerste plaats gericht 
op recidief, gedefinieerd als een toename van de TPED van ten minste 30° ten opzichte 
van de resultaten zes weken postoperatief. Een totaal van 115 handen bij 111 patiënten 
waren beschikbaar voor follow-up na 3 jaar (8 patiënten met 8 handen waren lost to 
follow-up). Deze tussentijdse analyse toonde een recidief na PNF in 64% van de geval-
len. Recidieven na PNF kwamen significant vaker voor dan na SF (9%) (p = 0,005). 
Tevens bleek dat jongere patiënten  sneller een recidief ontwikkelen na behandeling 
voor de ziekte van Dupuytren, onafhankelijk welke behandeling die zij ontvingen. 
Tevredenheid met de resultaten van de behandeling was hoog in beide groepen, maar 
de SF-groep scoorde  hoger dan de PNF groep. Toch kozen patiënten die eerder PNF 
hadden ondergaan die een recidief ontwikkelden velen male opnieuw PNF als behan-
deling voor het recidief.
Hoofdstuk zes  schetst de 5-jaars resultaten van de studie. Van de oorspronkelijke 
populatie van patiënten beschreven in de hoofdstukken 3 en 4, waren 93 patiënten 
met 96 handen beschikbaar voor onderzoek. Na 5 jaar is het recidiefpercentage in de 
PNF groep met 84,9% aanzienlijk hoger dan het percentage in de SF-groep (20,9%), 
p <0,001, en traden recidieven veel eerder op in de PNF groep (p = 0,001). Hogere 
leeftijd ten tijde van de behandeling werd opnieuw van significante invloed bevonden 
op het ontstaan van een recidief, waarbij hogere leeftijd ten tijde van de behandeling 
protectief is, p = 0.005. Er werd geen bewijs gevonden dat Dupuytren’s diathese de 
recidiefkans beïnvloedt. De tevredenheid was hoog in beide groepen, maar in de SF 
groep significant hoger dan in de PNF groep. Toch kozen veel patiënten (53%) om hun 
recidief opnieuw te laten behandelen middels PNF.
Vergelijking van de resultaten van PNF en SF met beschikbare resultaten van de be-
handeling met van Clostridium Histolyticum afkomstig collagenase bleek dat op lange 
termijn de resultaten van SF beter zijn dan die van collagenase. Een enkele behande-
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ling met PNF, echter, lijkt enigszins inferieur aan drie injecties met collagenase. Reci-
diefkans na behandeling met collagenase is vergelijkbaar, zo niet slechter dan de PNF 
recidiefkans na 5 jaar.
De onderstaande grafiek toont het aantal handen in de studie ten tijde van aanvang,  
na 6 weken, 3 jaar en 5 jaar. 
Grafiek 1: Aantal handen in de studie aan de start, na 6 weken, 3 jaar en na 5 jaar.
Hoofdstuk zeven presenteert de korte en lange termijn resultaten van de PNF bij de 
behandeling van recidief Dupuytren.
Dertig patiënten met een recidief uit de RCT, met een totaal van 40 stralen in 30 
handen, werden bestudeerd. De gemiddelde follow-up na PNF was 4,4 jaar. Primaire 
uitkomstmaten waren vermindering van het TPED, en interval tot een tweede recidief, 
waarbij “recidief ” gedefinieerd werd als een stijging van meer dan 30˚ van het TPED  
per straal ten opzichte van het resultaat op het einde van de vorige behandeling.
Onmiddellijke resultaten waren goed: de vermindering van het extensiedeficit bedroeg 
76%. PNF was vooral effectief ter plaatste van het MCP gewricht, met een gemiddelde 
reductie van het deficit van 93%, terwijl de gemiddelde daling van het deficit in het 
PIP gewricht 57% bedroeg. Vijftig procent van de gevallen bleef tijdens de follow-up 
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vrij van een tweede recidief. De overige vijftig procent van de patiënten kreeg opnieuw 
een recidief, welke na gemiddeld 1.4 jaar werd behandeld. Door middel van twee keer 
PNF, kon een meer invasieve behandeling zoals SF gemiddeld 2,9 jaar uit gesteld wor-
den.
Uit deze studie valt te concluderen dat PNF ook effectief kan worden toegepast voor 
recidief Dupuytren: 50% van de gevallen bleef vrij van recidief voor een gemiddelde 
van 4,4 jaar. Als er een tweede recidief optreedt, gebeurt dit relatief vroeg na de be-
handeling: patiënten moeten dus bereid zijn om deze onzekerheid te aanvaarden in 
het kader van de voordelen van PNF, zoals snel herstel, weinig complicaties en een 
minimale invasiviteit.
Hoofdstuk acht  geeft een systematische review van de resultaten van verschillende 
chirurgische behandelingen voor de ziekte van Dupuytren, gericht op de verschillende 
criteria die werden gebruikt om de “het succes van een behandeling”  en de definitie 
van een recidief te definiëren. Deze studie werd geïnitieerd in nauwe samenwerking 
met de Amerikaanse Collagenase Study Group. literatuuronderzoek werd uitgevoerd in 
januari 2011 naar het gebruik van de termen “Dupuytren” EN (“fasciectomy” OF “fas-
ciotomie” OF “dermofasciectomy” OF “aponeurotomy” OF “aponeurectomy”) waarbij 
werd beperkt tot studies in het Engels.
Deze zoekopdracht leverde 218 artikelen op, in slechts 21 gevallen bleken duidelijke 
definities van de uitkomst parameters te zijn gebruikt, werden kwantitatieve resulta-
ten vermeld voor correctie van de contractuur en recidief, en werden ten minste 20 
patiënten beschreven. Definities voor behandelingsresultaat en recidief varieerden 
sterk tussen de verschillende studies en waren bijna altijd kwalitatief. Het percentage 
patiënten dat een correctie van de contractuur bereikte na een operatie varieerde 
van 15% tot 96,2%. Recidiefpercentages liepen uiteen van 4,9% tot 73%. Deze evalu-
atie onderstreepte opnieuw de variabiliteit van de uitkomstmaten, de definities en de 
duur van de follow-up, welke een vergelijking van ons werk met dat van anderen ook 
al had belemmerd. Deze studie toont aan dat duidelijke objectieve definities voor de 
behandelingsresultaten en recidieven nodig zijn voor een zinvolle vergelijking van de 
resultaten van verschillende chirurgische ingrepen.
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De belangrijkste conclusies van dit proefschrift luiden als volgt:
1. PNF is het meest geschikt voor oudere patiënten en voor degenen die bereid zijn 
om het nadeel van een mogelijk vroegtijdig recidief te aanvaarden, en voor hen 
die willen profiteren van voordelen zoals snel herstel, lage kans op complicaties 
en een minimale invasiviteit.
2. SF is nog steeds een zeer betrouwbare behandelingsmodaliteit,  met als het grote 
voordeel dat recidieven minder snel en minder vaak optreden dan na PNF. Het 
grote nadeel is dat het een veel langere revalidatie periode kent. Omdat de kans 
op het ontstaan van een recidief leeftijdsgebonden is, is SF mogelijk een betere 
behandelingskeuze voor de jongere leeftijdsgroep.
3. PNF kan ook worden uitgevoerd in het geval van recidiverende ziekte. Het zal 
de helft van de patiënten “genezen”, en op zijn minst stelt het meer invasieve 
behandelingen uit voor de andere helft van de patiënten.
4. Doordat duidelijk omschreven definities in de literatuur over de behandeling van 
de ziekte van Dupuytren ontbreken, zijn vergelijkingen tussen de verschillende 
studies moeilijk te maken.
De waarde van dit proefschrift ligt in de gerandomiseerde vergelijking van de SF met 
PNF, en het feit dat voor aanvang van de RCT een pilotstudy werd uitgevoerd om te 
testen of onze behandelingsresultaten vergelijkbaar waren met die in andere studies. 
Daarnaast hebben wij als eerste onderzocht of PNF effectief is in het geval van recidi-
verende ziekte. Op deze wijze is een bijdrage geleverd aan de evidence-based weten-
schappelijke kennis van de behandeling van patiënten met de ziekte van Dupuytren.
Echter, terugkijkend zien we ook een aantal tekortkomingen en fouten van dit project. 
Hiervan geven wij een gedetailleerde beschrijving om deze te voorkomen bij eventuele 
toekomstige studies.
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Randomisatie
Patiënten werden gerandomiseerd in de twee behandelingsgroepen door het wille-
keurig trekken van een verzegelde envelop met daarin een briefje met hetzij SF, hetzij 
PNF. In een recente studie van Becker en Davis werd deze methode aangeduid als 
“pseudo-randomisatie ‘.  Hoewel we het niet eens met deze term, zullen we voor toe-
komstige studies gebruik maken van een computergestuurde randomisatie (Kang 2008, 
Becker en Davis 2011).
Behandeling
Aan het begin van de studie waren we relatief onervaren in het gebruik van PNF. Der-
halve hebben we een pilotstudy verricht om te onderzoeken of onze resultaten verge-
lijkbaar waren met die van anderen. En inderdaad waren deze resultaten vergelijkbaar, 
dus voelden wij ons gesterkt in het starten van een gerandomiseerde studie.
Nu, met bijna 10 jaar ervaring met PNF hebben wij meer durf en aarzelen niet om PNF 
toe te passen in de buurt van de neurovasculaire bundels. We hebben ervaren dat dit 
veilig is, zolang alleen de huid is verdoofd. Het is zeer goed mogelijk dat onze huidige 
resultaten in het geval van Tubiana  stadium 3 en 4 beter zijn dan die van onze RCT 
door agressievere therapie.
Tijdens de RCT werd één zenuw beschadigd tijdens het verrichten van een SF. Het was 
de ulnaire zenuw van digitus 4 in een geval waarbij alleen deze vinger was aangetast: 
de zenuw werd omhoog getrokken, samen met het omliggende vetweefsel. Dit letsel 
werd veroorzaakt door onoplettendheid en had moeten worden voorkomen.
Patiënt vragenlijsten
In de eerste 6 weken na de behandeling in de RCT vroegen we alle patiënten een Ne-
derlandse vertaling van de DASH vragenlijst en de Short Form (SF) -36 in te vullen. 
De Nederlandse vertaling van de DASH vragenlijst is een gevalideerd instrument dat 
gebruikt kan worden om een functionele beperking van de bovenste extremiteit  te 
scoren (Hunsaker 2002, Veehof 2002). Deze vragenlijst bestaat uit 30 items die betrek-
king hebben op invaliditeit en symptomen van de bovenste ledematen op een schaal 
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van 0 tot 5. De scores worden opgeteld en omgezet in een 100-punts schaal. Hoe lager 
de score, hoe minder beperkingen ervaren worden. De SF-36 is een gezondheidsenquê-
te met 36 vragen. Met behulp van deze vragenlijst wordt de kwaliteit van leven geme-
ten. (Ware en Sherbourne 1992) De SF-36 bestaat uit acht scores, die berekend worden 
door een gewogen som te bereken van de vragen in één sectie. Deze wordt vervolgens 
omgezet in een 0-100 schaal.
Van de SF-36 was in 1999 al bekend dat de respons bij patiënten ouder dan 65 jaar en 
bij patiënten met een cognitieve of fysieke handicap te laag is om te worden gebruikt 
(Andresen 1999). Deze bevindingen zijn niet meegenomen bij het ontwerp van het 
protocol, maar tijdens de studie bleek deze tekortkoming, doordat de antwoorden die 
de patiënten gaven inconsistent waren. In onze studie was de gemiddelde leeftijd bij 
aanvang 63 jaar oud. In de beschrijving van onze resultaten hebben we besloten om 
alle gegevens van de SF-36 niet te gebruiken gezien het hoge percentage van ongeldig 
ingevulde vragenlijsten.
In het DASH score systeem moeten ten minste 27 van de 30 items worden gescoord 
om een betrouwbaar resultaat te geven. De DASH-score vragenlijsten aan het begin 
van de studie en in de directe postoperatieve periode werden door de meeste patiënten 
correct ingevuld. Echter, naarmate de tijd vorderde tijdens de studie, bleken slechts 
weinig patiënten bereid de lange vragenlijst keer op keer in te vullen. Dit resulteerde 
in een te hoge uitval, waardoor de DASH vragenlijst nutteloos was. In 2006 werd de 
QuickDASH ontwikkeld. Dit is een veel kortere vragenlijst met een betrouwbaar resul-
taat bij de ziekte van Dupuytren (Budd 2011). Als deze beschikbaar was geweest aan 
het begin van onze studie, zou dit een veel beter alternatief zijn geweest.
Een andere tekortkoming van de DASH scores is dat ze niet erg specifiek zijn voor 
handproblematiek. Voor toekomstige studies, zijn de PEM, MHQ, PRWHE en de zeer 
recent gepresenteerde Southhampton’s Dupuytren Scoring Scheme en URAM scoring 
systems alternatieven die het overwegen waard zijn (Bindra 2003, Changulani 2008, 
Van de Ven-Stevens 2009, Warwick, onlangs ingediend voor publicatie 2011, Beaudri-
eul 2011)
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Alle patiënten werd gevraagd om de vragenlijsten thuis in te vullen elke week na de 
behandeling, tot 6 weken na de behandeling. Twee patiënten vulden deze vragenlijst in 
het geheel nooit in en om deze reden werden ze uitgesloten voor de verdere follow-up. 
We hebben nu het gevoel dat dit niet nodig was: we hadden ze beter voor de langere 
termijn follow-up in de studie kunnen laten.
Follow-up onderzoek
Een onafhankelijk onderzoeker verrichtte de meeste, maar niet alle follow-up onder-
zoeken. In toekomstige studies zou dit altijd verricht moeten worden door een persoon 
die niet betrokken is bij de studie.
PNF in het geval van recidief
De studie naar de resultaten van PNF in het geval van recidief Dupuytren is niet per-
fect ontworpen. Uiteraard was de grootte van de groep vrij klein, omdat deze alleen 
bestond uit patiënten van onze RCT met een recidief (30 patiënten). Dit maakte het 
moeilijk om te bewijzen of bekende risicofactoren invloed hadden op het ontstaan van 
een tweede recidief. Mogelijk was er ook een selectie bias (patiënten werden niet wil-
lekeurig toegewezen aan een van de behandelingsmodaliteiten:  PNF of SF), mogelijk 
veroorzaakte dit de gunstiger resultaten. Echter gezien het feit dat dit de eerste studie 
ooit is naar de effectiviteit en lange termijn resultaten van PNF, denken wij dat het 
toch de moeite waard is om te publiceren.
Definities
Zoals vermeld in alle hoofdstukken over de recidieven, is het begrip recidief slecht 
gedefinieerd waar het gaat om de ziekte van Dupuytren. Dit maakt een vergelijking 
met eerder gerapporteerde studies bijna onmogelijk. De meest gebruikte definitie is 
“terugkeer van de weefsels van Dupuytren in een eerder geopereerde zone” (McFarlane 
1990, Becker 2010). Deze definitie van recidief kan niet worden gebruikt in dit onder-
zoek, omdat bij PNF geen weefsel wordt verwijderd. Noduli die aanwezig zijn voor de 
procedure blijven vaak onveranderd of worden op zijn best zachter. De strengen wor-
den doorsneden, maar na verloop van tijd lijken deze opnieuw te verbinden. Voor deze 
studie is dan ook gebruik gemaakt van een meer indirecte, maar kwantitatieve defini-
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tie voor herhaling: een verslechtering van het totale Passive Extensie Deficit (TPED) 
van 30º of meer in een straal ten opzichte van het resultaat 6 weken na de behandeling. 
Deze definitie is reproduceerbaar en klinisch relevanter dan de andere definities, want 
het is de progressie van de contractuur die uiteindelijk leidt tot functionele proble-
men en tot het verzoek om een reïnterventie uit te voeren, terwijl de terugkeer van 
het weefsel van Dupuytren niet noodzakelijk de handfunctie nadelig beïnvloedt, noch 
de indicatie voor behandeling is. Gekozen is voor een verslechtering van 30 º, omdat 
dit overeenkomt met Hueston’s tabletoptest en omdat het de minimale contractuur is 
waarbij een patiënt in aanmerking komt voor een operatie in ons behandelcentrum.
In de studies betreffende de werkzaamheid van Clostridium Histolyticum afgeleid 
Collagenase, die net als onze studies werden ontworpen in de laatste tien jaar, wer-
den andere indicaties voor behandeling (contractuur van> 20˚), resultaten en recidief  
gebruikt (Hurst 2009, Watt 2010, Gilpin 2010 ). Omdat het FDA-goedgekeurde proto-
col alleen toegestaan was voor de behandeling van een gewricht, werden de effecten 
hiervan ook per gewricht vermeld en niet per straal zoals in onze studies. De auteurs 
beschouwen een behandeling als “klinisch succesvol” als de correctie van de afwijking 
binnen 0-5˚ van volledige extensie was. Dit is in wetenschappelijke zin een waardevol-
le aanvulling op de defintitie die in onze studies werd gebruikt, het reductiepercentage 
voor een complete straal. Echter, een succesvolle behandeling in een MCP gewricht is 
op geen enkele wijze een succesvolle behandeling van de hele straal, laat staan van de 
hele hand: een afwijkende stand van andere gewrichten in de hand kan de functie van 
de hand nog fors beperken, en de handfunctie is hetgeen het succes van de behande-
ling van de ziekte van Dupuytren bepaalt. Daarom zijn wij van mening dat men niet 
alleen resultaten dient te rapporteren per gewricht, maar ook voor een complete straal 
en de gehele hand.
Daarnaast worden in studies over recidief na behandeling met collagenase, alleen de 
met “klinisch succes” behandelde gewrichten vervolgd  bij het analyseren van het re-
cidiefpercentage (Hurst 2009, Watt 2010, Xiaf lex persbericht 2011). Dit is een mislei-
dende manier van datapresentatie. In recent gepubliceerde  gegevens over de werk-
zaamheid van Collagenase bijvoorbeeld, bereikten slechts 623 van de 1568 behandelde 
gewrichten klinisch succes (39,7%), en bereikten dus 945 deze uitkomstmaat niet. Na 
3 jaar,  was er sprake van recidief in 217 gewrichten, gedefinieerd als een toename van 
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de PED van ten minste 20˚. Dit komt overeen met een recidiefpercentage van 34,8% 
(217/623), terwijl het recidiefpercentage van de andere subgroep onbekend is, wat 
uiteraard zorgt voor een bias.
In de voorliggende studie vielen alle behandelde stralen van één hand uit de studie 
wanneer er in één van deze stralen zich een recidief voordeed. Achteraf was het mis-
schien beter geweest de overige stralen te vervolgen.
De thema’s over definities van de succesvolle behandeling en recidief gaven ons zo veel 
stof tot nadenken, dat wij samen met twee Amerikaanse collega’s, Drs Denkler en Drs 
Pess uit de collagenase werkgroep besloten om een systematische review over het on-
derwerp te schrijven. Deze review werd uitgevoerd in januari 2010 en daarmee konden 
wij onze eigen vijf jaars resultaten, hoewel voor ons zelf reeds beschikbaar, niet opne-
men in de resultaten. Het combineren van de resultaten van deze systematische review 
met onze eigen ervaring leidt tot de volgende adviezen voor toekomstig onderzoek:
TOEKOMSTPERSPECTIEVEN
Idealiter zouden interventies voor de ziekte van Dupuytren moeten worden onderzocht 
in grootschalige, gerandomiseerde, dubbelblinde, gecontroleerde klinische studies met 
goed gedefinieerde patiëntenpopulaties en tijdstippen voor de evaluatie. Als rando-
misatie onmogelijk of onpraktisch is, moeten grote cohorten worden gebruikt, zodat 
gematcht kan worden op patiëntkenmerken en de ernst van de contractuur. Met alle 
diathesekenmerken moet rekening worden gehouden, evenals met bijkomende ziekten 
zoals diabetes mellitus en lever-en vaatziekten, en omgevingsfactoren, zoals roken, 
alcoholgebruik en blootstelling aan trillingen (Descatha 2011).
Dubbele blindering is bijna onmogelijk in studies die chirurgische ingrepen vergelij-
ken. Blinderen van de onderzoeker die de follow-up uitvoert kan worden bereikt door 
het gebruik van niet-transparante, nauwsluitende handschoenen.
Wanneer elke studie dezelfde definitie van recidief zou gebruiken, die van toepassing 
zou zijn op iedere behandelingsmodaliteit,  zou vergelijking tussen verschillende inter-
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venties mogelijk zijn. De volgende definitie van recidief is aan te raden: een toename 
van de TPED van een vast aantal graden (20 of 30°) in vergelijking met de directe 
postoperatieve metingen in de behandelde straal. Extensie moet worden gedefinieerd 
als een toename van 20-30° TPED in een straal buiten het behandelde gebied. Op 
deze manier zijn zowel recidief als extensie klinisch relevant voor de patiënt, daar de 
handfunctie verslechtert wanneer Hueston’s tabletoptest positief is. Bovendien moe-
ten de goniometrische waarden van elk gewricht worden opgenomen in een database 
om vergelijking tussen verschillende studies mogelijk te maken. Follow-up onderzoek 
dient plaats te vinden op vaste tijdstippen en bij voorkeur op de termijn van één week, 
4-6 weken, 6 maanden en jaarlijks tot ten minste vijf jaar na de behandeling.
Vele nieuwe veelbelovende technieken zijn momenteel in ontwikkeling bij de behan-
deling van de ziekte van Dupuytren. Zeer recent werd een onderzoek gepubliceerd 
waarbij uitgebreide percutane aponeurotomie verricht werd in combinatie met lipo-
grafting (Hovius 2011). De auteurs vonden de resultaten van de reguliere aponeuro-
tomie teleurstellend en voegden vet subcutaan toe, als interpositie tussen de huid en 
fascia, maar ook om het relatieve tekort aan onderhuids vet te herstellen. Korte ter-
mijn resultaten zijn veelbelovend: bij 50 patiënten die werden behandeld, varieerde de 
gemiddelde verbetering van 56,4% tot 114%, en 88% van de patiënten bereikte Tubiana 
stadium I na de behandeling. De lange termijn resultaten zijn op dit moment nog niet 
beschikbaar.
Ook worden vele studies uitgevoerd naar de behandeling met collagenase (Badalamen-
te 2000, 2002, 2007, Hurst 2009, Watt 2010). Het zou interessant zijn om collagenase 
te vergelijken met andere behandelingen van de ziekte van Dupuytren om te zien of dit 
echt een goed alternatief is. In de nabije toekomst zullen meer gegevens beschikbaar 
komen met betrekking tot de lange termijn resultaten en de effectiviteit.
In Duitsland wordt door sommigen radiotherapie toegepast bij een vroeg stadium van 
Dupuytren (Betz 2010).
Er moet echter meer onderzoek worden gedaan, niet alleen op effectiviteit en veilig-
heid van deze technieken, maar nog belangrijker, om de resultaten van deze behan-
delingen te vergelijken bij gelijke groepen op een gerandomiseerde, gecontroleerde 
manier. 
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In deze studie is voor het eerst aangetoond dat een hogere leeftijd ten tijde van de be-
handeling het risico op recidief vermindert. Het zou interessant zijn om te zien of dit 
opnieuw kan worden bevestigd in grotere studies, en om te zien of er een ander advies 
over de behandeling moet worden gegeven aan verschillende leeftijdsgroepen.
Een andere onbeantwoorde vraag blijft wat de rol is van de postoperatieve hand- en 
spalktherapie bij de behandeling van Dupuytren. Hoewel het routinematig spalken 
na fasciectomie en dermatofaciectomie de range of motion en de functie niet lijkt te 
verbeteren, is er mogelijk plaats voor spalken na de minder invasieve behandelingen, 
zoals PNF, collagenase, of radiotherapie (Meinel, 2011, Jerosch-Herold 2011 ).
Last but not least, is er zeer weinig literatuur beschikbaar over de behandeling van 
recidieven, onafhankelijk welke techniek wordt gebruikt. Recidieven komen zeer vaak 
voor, ongeacht welke initiële behandelingsmodaliteit wordt gebruikt. Het zou heel 
interessant zijn om te onderzoeken welke behandeling superieur is bij de behandeling 
van een recidief, of de verschillende leeftijdsgroepen andere resultaten hebben na de 
behandeling voor het recidief en of spalken of handtherapie van enig nut zijn na de 
behandeling van het recidief.
We hebben aangetoond dat PNF een waardig alternatief is bij de behandeling van 
recidieven. Verder onderzoek met grotere groepen patiënten is nodig om de specifieke 
indicaties te definiëren. En hopelijk zullen we in de toekomst in staat zijn om de resul-
taten van PNF met andere behandelingen voor recidieven te vergelijken. Dit kan alleen 
gedaan worden als gestandaardiseerd en goed beschreven definities voor recidief en de 
resultaten van de behandelingen worden gebruikt.
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